<?xml version="1.0" encoding="UTF-8"?>
<addis-data xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xsi:noNamespaceSchemaLocation="http://drugis.org/files/addis-1.xsd">
	  <indications>
      <indication code="310497006" name="Severe depression"/>
   </indications>
	  <endpoints>
      <endpoint name="CGI Severity Change"
                description="Change from baseline CGI Severity of Illness score">
         <continuous direction="HIGHER_IS_BETTER"
                     unitOfMeasurement="Deviation from the baseline of CGI Severity of Illness score"/>
      </endpoint>
      <endpoint name="Dropouts"
                description="Number of patients dropping out of the study prematurely">
         <rate direction="LOWER_IS_BETTER"/>
      </endpoint>
      <endpoint name="HAM-D Responders"
                description="Responders with a 50% increase in HAM-D score">
         <rate direction="HIGHER_IS_BETTER"/>
      </endpoint>
      <endpoint name="MADRS Responders"
                description="Responders with a 50% increase in MADRS score">
         <rate direction="HIGHER_IS_BETTER"/>
      </endpoint>
   </endpoints>
	  <adverseEvents>
      <adverseEvent name="Abdominal Pain" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Abnormal Ejaculation" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Accommodation Disturbances" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Agitation" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Anorexia" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Anxiety" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Appetite Increased" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Asthenia" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Back Pain" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Blurred Vision" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Bronchitis" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Chest Pain" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Concentration Difficulties" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Constipation" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Depersonalization" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Diarrhea" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Diminished Sexual Desire" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Dizziness" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Dream Abnormality" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Dry Mouth" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Dysmenorrhea" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Dyspepsia" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Emotional Indifference" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Erectile Dysfunction" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Failing Memory" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Fatigue" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Flatulence" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Flu Syndrome" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Gastralgia" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Headache" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Impotence" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Increased Duration Of Sleep" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Increased Salivation" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Increased Sexual Desire" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Infection" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Insomnia" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Micturation Disturbances" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Nausea" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Nervousness" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Orgasmic Dysfunction" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Orgiastic Dysfunction" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Pain" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Palpitation" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Pharyngitis" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Rash" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Reduced Salivation" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Reduced Sleep" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Respiratory Disorder" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Rhinitis" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Sexual Dysfunction" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Somnolence" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Sweating" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Tinnitis" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Tremor" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Vertigo" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Vomiting" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Weight Gain" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
      <adverseEvent name="Weight Loss" description="">
         <rate direction="LOWER_IS_BETTER"/>
      </adverseEvent>
   </adverseEvents>
	  <drugs>
      <drug name="Bupropion" atcCode="N06AX12"/>
      <drug name="Citalopram" atcCode="N06AB04"/>
      <drug name="Duloxetine" atcCode="N06AX21"/>
      <drug name="Escitalopram" atcCode="N06AB10"/>
      <drug name="Fluoxetine" atcCode="N06AB03"/>
      <drug name="Fluvoxamine" atcCode="N06AB08"/>
      <drug name="Mirtazapine" atcCode="N06AX11"/>
      <drug name="Paroxetine" atcCode="N06AB05"/>
      <drug name="Placebo" atcCode="Placebo"/>
      <drug name="Sertraline" atcCode="N06AB06"/>
      <drug name="Venlafaxine" atcCode="N06AX16"/>
   </drugs>
	  <populationCharacteristics/>
	  <studies>
      <study name="Aberg-Wistedt et al, 2000">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>Relatively little research is available comparing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) during continuation therapy. This investigation reports the differential effect of 6 months of treatment with sertraline versus paroxetine for symptoms of depression, quality of life, and personality outcomes.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The subjects were male and female outpatients, aged 18 years and older, who met DSM-III-R criteria for major depression and who had a 10-item Montgomery-Åsberg Depression Rating Scale (MADRS)9  score of 21 or more at baseline, with less than 25% improvement on the MADRS during the washout period. Enrollment of fertile women was contingent upon a negative result on a pregnancy test and stable use for 3 months of medically accepted contraception before study entry.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>(1) current or past history of mania or hypomania, alcoholism or substance abuse, dementia, or epilepsy; (2) presence of psychotic depression or organic affective illness; (3) history of suicide attempts or current high suicide risk (&gt;4 on item 10 of the MADRS); (4) current use of any psychotropic medication, except for the use of one of three hypnotic/anxiolytic medications (nitrazepam [2.5-10 mg], flunitrazepam [0.5-2 mg], or oxazepam [15-25 mg]); (5) treatment with lithium in the month prior to the screening or with a monoamine oxidase inhibitor in the 2 weeks before the screening; (6) a history of significant intolerance or allergic reaction to sertraline or paroxetine; and (7) evidence of clinically significant hepatic or renal disease, any other acute or unstable medical condition, or use of any concomitant medication that might interfere with the safe conduct of the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>11106136</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Erectile Dysfunction">
               <adverseEvent name="Erectile Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Palpitation">
               <adverseEvent name="Palpitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dream Abnormality">
               <adverseEvent name="Dream Abnormality"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Loss">
               <adverseEvent name="Weight Loss"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire">
               <adverseEvent name="Diminished Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction">
               <adverseEvent name="Orgasmic Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Increased Duration Of Sleep">
               <adverseEvent name="Increased Duration Of Sleep"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Gain">
               <adverseEvent name="Weight Gain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Reduced Salivation">
               <adverseEvent name="Reduced Salivation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Accommodation Disturbances">
               <adverseEvent name="Accommodation Disturbances"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="83" size="177">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="85" size="176">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Accommodation Disturbances"/>
               <arm id="85"/>
               <rateMeasurement rate="20" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="83"/>
               <rateMeasurement rate="16" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="83"/>
               <rateMeasurement rate="39" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="85"/>
               <rateMeasurement rate="27" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="83"/>
               <rateMeasurement rate="26" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="85"/>
               <rateMeasurement rate="15" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="83"/>
               <rateMeasurement rate="49" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="85"/>
               <rateMeasurement rate="30" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="85"/>
               <rateMeasurement rate="20" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="83"/>
               <rateMeasurement rate="158" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="85"/>
               <rateMeasurement rate="33" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="83"/>
               <rateMeasurement rate="18" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="85"/>
               <rateMeasurement rate="12" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="85"/>
               <rateMeasurement rate="13" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="85"/>
               <rateMeasurement rate="64" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="83"/>
               <rateMeasurement rate="19" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="85"/>
               <continuousMeasurement mean="-2.6" sampleSize="176" stdDev="1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="83"/>
               <rateMeasurement rate="12" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Increased Duration Of Sleep"/>
               <arm id="85"/>
               <rateMeasurement rate="8" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="85"/>
               <rateMeasurement rate="19" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="83"/>
               <continuousMeasurement mean="-2.5" sampleSize="177" stdDev="1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="85"/>
               <rateMeasurement rate="20" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Increased Duration Of Sleep"/>
               <arm id="83"/>
               <rateMeasurement rate="27" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Reduced Salivation"/>
               <arm id="83"/>
               <rateMeasurement rate="26" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="83"/>
               <rateMeasurement rate="0" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Reduced Salivation"/>
               <arm id="85"/>
               <rateMeasurement rate="19" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="85"/>
               <rateMeasurement rate="5" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Erectile Dysfunction"/>
               <arm id="85"/>
               <rateMeasurement rate="11" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="83"/>
               <rateMeasurement rate="61" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="83"/>
               <rateMeasurement rate="46" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="85"/>
               <rateMeasurement rate="157" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="83"/>
               <rateMeasurement rate="30" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Erectile Dysfunction"/>
               <arm id="83"/>
               <rateMeasurement rate="8" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="83"/>
               <rateMeasurement rate="9" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="83"/>
               <rateMeasurement rate="24" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="85"/>
               <rateMeasurement rate="37" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Accommodation Disturbances"/>
               <arm id="83"/>
               <rateMeasurement rate="22" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="85"/>
               <rateMeasurement rate="36" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="83"/>
               <rateMeasurement rate="59" sampleSize="177"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="85"/>
               <rateMeasurement rate="22" sampleSize="176"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Alves et al, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. (Primary Care Psychiatry, 1999; 5:57-63)</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>3</value>
               <notes/>
            </centers>
            <objective>
               <value>A 12 week double-blind, randomized comparison of the efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Males or females aged 18-65 years were eligible for the study if they met DSM-IV diagnostic criteria for major depression, had a minimum score of 20 on the 21-item HAM-D scale and had less than a 20% decrease in HAM-D score between screening and baseline. Women of childbearing potential were required to have a negative urine beta-human chorionic gonadotropin test prior to study entry and had to use a medically acceptable form of contraception (hormonal, intrauterine device or combination of barrier methods) throughout the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had known sensitivity to venlafaxine or fluoxetine. In addition, patients with a history of any clinically significant cardiac, hepatic or renal disease or clinically significant abnormalities on a screeing physical examination, electrodiagram (ECG) or laboratory tests were excluded. Patients with any mental or neurologic disorder were also excluded (narrow anlge glaucoma, urinary retention, a history of a seizure disorder, a history of bipolar disorder, or a history of drug or alcohol dependence). Women who were breast-feeding were not eligible. Patients where preculded from participation if they had used any investigational drug, antipsychotic drug, electroconvulsive therapy or sumatriptan within 30 days of the baseline, fluoxetine within 21 days, a monoamine oxidase inhibitor within 14 days or other antidepressants, anxiolytic or sedative-hypnotic drug (except diazepam) within 7 days. The use of other drugs with psychotropic effects (e.g. beta-adrenergic blockers) within 7 days wasy prohibited unless a stable dose had been maintained for at least 3 months.</value>
               <notes/>
            </exclusion>
            <references/>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="173" size="40">
               <flexibleDose minDose="75.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="175" size="47">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="173"/>
               <rateMeasurement rate="32" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="173"/>
               <rateMeasurement rate="3" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="173"/>
               <rateMeasurement rate="2" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="175"/>
               <rateMeasurement rate="26" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="175"/>
               <rateMeasurement rate="1" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="173"/>
               <rateMeasurement rate="3" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="173"/>
               <rateMeasurement rate="13" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="175"/>
               <rateMeasurement rate="1" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="173"/>
               <rateMeasurement rate="6" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="175"/>
               <rateMeasurement rate="4" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="175"/>
               <rateMeasurement rate="1" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="175"/>
               <rateMeasurement rate="3" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="175"/>
               <rateMeasurement rate="5" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="173"/>
               <rateMeasurement rate="4" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="175"/>
               <rateMeasurement rate="1" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="173"/>
               <rateMeasurement rate="4" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="175"/>
               <rateMeasurement rate="13" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="173"/>
               <rateMeasurement rate="1" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="175"/>
               <rateMeasurement rate="30" sampleSize="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="173"/>
               <rateMeasurement rate="25" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="173"/>
               <rateMeasurement rate="10" sampleSize="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="175"/>
               <rateMeasurement rate="9" sampleSize="47"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Ballus et al, 2000">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>To compare the efficacy and tolerability of venlafaxine and paroxetine in patients with major depression or dysthymia.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men or women, aged 18-70 years, were eligible for the study if they met ICD-10 diagnostic criteria for mild to moderate depression or for dysthemia, had a minimum baseline score of 17 on the 21-item HAM-D scale and less than a 20% decrease in HAM-D score between screening and baseline. Women were required to have a negative urine beta-human chorionic gonadotropin test prior to study entry and to use a medically acceptable form of contraception throughout the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had known sensitivity to venlafaxine or paroxetine. Those patients with a history of any clinically significant cardiac, hepatic or renal disease or clinically significant abnormalities on a screening physical examination, electrocardiogram (ECG), or laboratory tests were excluded. Specifically, patients with moderate to severe renal impairment (creatinine clearance &lt; 30 ml/min) were excluded. Women who were breastfeeding were excluded. Also excluded were patients with any organic mental disorder; acute suicidal tendencies; a history of a seizure disorder; history or presence of mania or any psychotic disorder not associated with depression; or history of drug or alcohol dependence within the past 2 years. Patients were excluded from participation if they were using any investigational drug, fluoxetine, antipsychotic drug or electroconvulsive therapy within 30 days; a monoamine oxidase inhibitor within 14 days; other antidepressant within 7 days; or benzodiazepine (except lormetazepam) or other anxiolytic drug that could not be withdrawn before baseline.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10836286</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vertigo">
               <adverseEvent name="Vertigo"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abdominal Pain">
               <adverseEvent name="Abdominal Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="226" size="41">
               <flexibleDose minDose="75.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="228" size="43">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="226"/>
               <rateMeasurement rate="0" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="226"/>
               <rateMeasurement rate="26" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="226"/>
               <rateMeasurement rate="16" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="228"/>
               <rateMeasurement rate="7" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="228"/>
               <rateMeasurement rate="3" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vertigo"/>
               <arm id="226"/>
               <rateMeasurement rate="0" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="228"/>
               <rateMeasurement rate="4" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="226"/>
               <rateMeasurement rate="2" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="228"/>
               <rateMeasurement rate="23" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="228"/>
               <rateMeasurement rate="3" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="226"/>
               <rateMeasurement rate="25" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="226"/>
               <rateMeasurement rate="6" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="228"/>
               <rateMeasurement rate="27" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="226"/>
               <rateMeasurement rate="1" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vertigo"/>
               <arm id="228"/>
               <rateMeasurement rate="3" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="226"/>
               <rateMeasurement rate="11" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="228"/>
               <rateMeasurement rate="1" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="226"/>
               <rateMeasurement rate="5" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="226"/>
               <rateMeasurement rate="7" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="226"/>
               <rateMeasurement rate="6" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="228"/>
               <rateMeasurement rate="11" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="226"/>
               <rateMeasurement rate="3" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="226"/>
               <rateMeasurement rate="1" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="228"/>
               <rateMeasurement rate="4" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="228"/>
               <rateMeasurement rate="17" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="228"/>
               <rateMeasurement rate="3" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal Pain"/>
               <arm id="226"/>
               <rateMeasurement rate="6" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="228"/>
               <rateMeasurement rate="4" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal Pain"/>
               <arm id="228"/>
               <rateMeasurement rate="3" sampleSize="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="228"/>
               <rateMeasurement rate="4" sampleSize="43"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Behnke et al, 2003">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>33</value>
               <notes/>
            </centers>
            <objective>
               <value>To prospectively compare the onset of antidepressant efficacy of mirtazapine orally disintegrating tablets and sertraline at dosages commonly used in clinical practice.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The patients were recruited from general and psychiatric practices and clinics. Patients (aged between 18 and 70 years) fulfilling DSM-IV criteria for major depressive episode and with a total score of &gt;= 18 on the first 17 items the HAM-D scale at baseline were eligible for inclusion in the study. A severely depressed patient was defined as having an HAM-D score at baseline of &gt;= 25.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>A current diagnosis of eating disorders, postpartum depression or anxiety disorders (DSM-IV), or a current or previous diagnosis of any other DSM-IV Axis I or Axis II diagnosis including bipolar disorder or schizophrenia were criteria for exclusion. Patients were also excluded if they had epilepsy or a history of seizure disorder or anticonvulsant treatment; were pregnant, lactating, or of childbearing potential and not taking adequate contraceptive measures; were a suicide risk; were suffering from alcohol/substance abuse, a chronic and unstable physical disease, or one that could explain the symptoms of depression, or clinically meaningful abnormal findings on physical examination. Other reasons for exclusion included an episode duration of less than 2 weeks, a current depressive episode of more than 12 months, a lack of response to at least 2 adequate antidepressant therapies during the current episode, and more than 2 previous episodes that did not respond to adequate antidepressant therapy.

Patients who had shown previous hypersensitivity to mirtazapine or sertraline or who had developed serotonergic syndrome on treatment with an SSRI were not permitted to enter the study. The following treatments had to be stopped within the indicated intervals before the start of active study medication: electroconvulsive therapy (3 months), depot neuroleptics (2 months), fluspirilene (1 month), fluoxetine (1 month), monoamine oxidase inhibitors (3 weeks), testosterone and its derivatives (1 week for oral formulations and 3 weeks for intramuscular), benzodiazepines (1 week), St John’s Wort (1 week), sertraline and mirtazapine (current episode), and other psychotropic drugs (1 week). Any formal psychotherapy must have been stopped at least 1 month prior to baseline. Patients were excluded if they used sildenafil or other similar agents.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12920411</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Appetite Increased">
               <adverseEvent name="Appetite Increased"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire">
               <adverseEvent name="Diminished Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Gain">
               <adverseEvent name="Weight Gain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abdominal Pain">
               <adverseEvent name="Abdominal Pain"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="296" size="169">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="298" size="176">
               <flexibleDose minDose="30.0" maxDose="45.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Mirtazapine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="296"/>
               <rateMeasurement rate="16" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Appetite Increased"/>
               <arm id="296"/>
               <rateMeasurement rate="2" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="296"/>
               <rateMeasurement rate="31" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="296"/>
               <rateMeasurement rate="3" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="298"/>
               <rateMeasurement rate="9" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="298"/>
               <rateMeasurement rate="20" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="296"/>
               <rateMeasurement rate="17" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="298"/>
               <rateMeasurement rate="116" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="298"/>
               <rateMeasurement rate="7" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="296"/>
               <rateMeasurement rate="15" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="298"/>
               <rateMeasurement rate="35" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="296"/>
               <rateMeasurement rate="12" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="296"/>
               <rateMeasurement rate="13" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="298"/>
               <rateMeasurement rate="2" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal Pain"/>
               <arm id="296"/>
               <rateMeasurement rate="10" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal Pain"/>
               <arm id="298"/>
               <rateMeasurement rate="10" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="298"/>
               <rateMeasurement rate="16" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="296"/>
               <rateMeasurement rate="9" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="298"/>
               <rateMeasurement rate="12" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Appetite Increased"/>
               <arm id="298"/>
               <rateMeasurement rate="16" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="296"/>
               <rateMeasurement rate="11" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="296"/>
               <rateMeasurement rate="38" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="296"/>
               <rateMeasurement rate="113" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="296"/>
               <rateMeasurement rate="31" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="296"/>
               <rateMeasurement rate="10" sampleSize="169"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="298"/>
               <rateMeasurement rate="25" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="298"/>
               <rateMeasurement rate="13" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="298"/>
               <rateMeasurement rate="41" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="298"/>
               <rateMeasurement rate="2" sampleSize="176"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="298"/>
               <rateMeasurement rate="21" sampleSize="176"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Benkert et al, 2000">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Mirtazapine compared with paroxetine in major depression</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>50</value>
               <notes/>
            </centers>
            <objective>
               <value>The aim was to compare the efficacy and tolerability of mirtazapine with those of paroxetine.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients (men or women, aged from 18 to 70 years) fulfilling DSM-IV criteria for major depressive episode21 and with a total score &gt;= 18 on the HAM-D-17 at the start and end of a placebo washout period were eligible for inclusion in the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Reasons for exclusion included a current depressive episode of more than 12 months’ duration, a lack of response to at least 2 adequate antidepressant therapies during the current episode, more than 3 previous episodes that did not respond to adequate antidepressant therapy, a reduction of &gt;= 25% in the HAM-D-17 score during the placebo washout period, suicide risk defined as a score of 4 to 6 on item 10 of the MADRS scale and current bipolar disorder, depressive disorder not otherwise defined, panic disorder (with or without agoraphobia), agoraphobia without a history of panic disorder, schizophrenia, organic mental disorder, eating disorder (anorexia or bulimia nervosa), specific phobia, social phobia, or generalized anxiety disorder. The latter 3 conditions were only considered as exclusion criteria if they caused clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Patients were also excluded if they were pregnant, lactating, or of childbearing potential and not taking adequate contraceptive measures; were suffering from alcohol/substance abuse or epilepsy; had a history of seizure disorder; had ever received treatment with an anticonvulsant for epilepsy or seizures; or had clinically meaningful physical disease or abnormal findings on physical examination or laboratory testing. The following treatments must have been stopped within the indicated intervals before the start of active study medication: electroconvulsive therapy, 3 months; depot neuroleptics, 2 months; fluoxetine, 4 weeks; benzodiazepines, 2 weeks; monoamine oxidase inhibitors, 2 weeks; paroxetine, current episode, and other psychotropic drugs, 1 week. Any supportive psychotherapy must have been stopped at least 4 weeks prior to study entry.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>11030486</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Pain">
               <adverseEvent name="Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Gain">
               <adverseEvent name="Weight Gain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Back Pain">
               <adverseEvent name="Back Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="366" size="134">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="368" size="135">
               <flexibleDose minDose="15.0" maxDose="45.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Mirtazapine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="366"/>
               <rateMeasurement rate="7" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="366"/>
               <rateMeasurement rate="5" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="368"/>
               <rateMeasurement rate="30" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="368"/>
               <rateMeasurement rate="79" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="366"/>
               <rateMeasurement rate="10" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="366"/>
               <rateMeasurement rate="11" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="368"/>
               <rateMeasurement rate="9" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="366"/>
               <rateMeasurement rate="9" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="366"/>
               <rateMeasurement rate="14" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="368"/>
               <rateMeasurement rate="4" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="368"/>
               <rateMeasurement rate="5" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="368"/>
               <rateMeasurement rate="12" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="368"/>
               <rateMeasurement rate="9" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="366"/>
               <rateMeasurement rate="11" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="368"/>
               <rateMeasurement rate="19" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="368"/>
               <rateMeasurement rate="15" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="366"/>
               <rateMeasurement rate="7" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="368"/>
               <rateMeasurement rate="10" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain"/>
               <arm id="368"/>
               <rateMeasurement rate="5" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="366"/>
               <rateMeasurement rate="10" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="368"/>
               <rateMeasurement rate="13" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="366"/>
               <rateMeasurement rate="11" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="368"/>
               <rateMeasurement rate="13" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="368"/>
               <rateMeasurement rate="3" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="366"/>
               <rateMeasurement rate="5" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="368"/>
               <rateMeasurement rate="20" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="366"/>
               <rateMeasurement rate="9" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="366"/>
               <rateMeasurement rate="11" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain"/>
               <arm id="366"/>
               <rateMeasurement rate="7" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="368"/>
               <rateMeasurement rate="6" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="368"/>
               <rateMeasurement rate="11" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back Pain"/>
               <arm id="366"/>
               <rateMeasurement rate="8" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="366"/>
               <rateMeasurement rate="7" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back Pain"/>
               <arm id="368"/>
               <rateMeasurement rate="2" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="366"/>
               <rateMeasurement rate="72" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="368"/>
               <rateMeasurement rate="12" sampleSize="135"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="366"/>
               <rateMeasurement rate="15" sampleSize="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="366"/>
               <rateMeasurement rate="32" sampleSize="134"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Bennie et al, 1995">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>Comparing the efficacy and safety of sertraline with those of fluoxetine when administered for 6 weeks to psychiatric outpatients with major depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients were recruited and screened by investigators at study centers in the United Kingdom. Male and female outpatients oer the age of 18 years with a primary Axis I diagnosis of major depression (single or recurrent) or bipolar disorder, depressed, according to DSM-III-R criteria, were eligible to enroll in the study. Standardized DSM-III-R diagnostic assessment interviews were employed at screening to identify whether patients had major depression; bipolar disorder, depressed; or depression with melancholia. Additionally, patients had to have a minimum score of 18 on the HAM-D-17 scale, and women had to be postmenopausal, surgically sterilized or practicing an adequate method of contraception for at least 3 months before study entry. To qualify for random assignment to double-blind therapy at the end of the single-blind washout period, patients were required to meet the following criteria: (1) a minimum score of 18 on the 17-item HAM-D, (2) less than 25% decrease in HAM-D score compared with that at screening, and (3) a higher score on the Raskin Depression Scale than on the Covi Anxiety Scale. Patients with concomitant medical conditions were allowed to participate in the study provided that the conditions were clearly not associated with the illness under study and that any required medications were not psychoactive agents and were unlikely to interact with the drugs.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients excluded from the study were those not meeting the DSM-III-R criteria for major depression or bipolar disorder, pregnant or lactating women, women of childbearing potential not practicing a reliable method of contraception, and women intending to become pregnant within 3 months of enrolling in the trial. Also excluded were patients who had received previous treatment with sertraline or fluoxetine, thos treated with monoamine oxidase inhibitors within 2 weeks or other antidepressant medications within one week of double-blind therapy, those treated with any other investigational or marketed product in another study within 1 month before enrolling in this trial, those treated with reserpine or methyldopa, and those patients likely to require additional treatment with psychoactive medication (escept occasional chloral hydrate or temazepam), electroconvulsive therapy (ECT), or intensive psychotherapy during the study period. Other reasons for exclusion were failure to respond to previous antidepressant therapy at clinically appropriate dosages, use of ECT to treat a previous episode of depression, any known contraindications to treatment with sertraline or fluoxetine including allergy or hypersensitivity, a history of severe allergies or multiple adverse events associated with pharmacotherapy, the presence of significant medical disease (including epilepsy), and the occurence of severe infection or major surgery within 1 month before double-blind therapy. Psychiatric histories including another Axis I disorder precluded enrollment in the study. Additionally, partients considered by the investigator to represent a significant suicide risk and those with conditions likely to invalidate informed consent or limit compliance with protocol requirements were not permitted to enter the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>7775364</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="452" size="142">
               <flexibleDose minDose="50.0" maxDose="100.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="454" size="144">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="452"/>
               <rateMeasurement rate="7" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="452"/>
               <rateMeasurement rate="5" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="454"/>
               <rateMeasurement rate="36" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="454"/>
               <rateMeasurement rate="21" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="452"/>
               <rateMeasurement rate="2" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="454"/>
               <rateMeasurement rate="63" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="454"/>
               <rateMeasurement rate="8" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="454"/>
               <rateMeasurement rate="6" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="452"/>
               <rateMeasurement rate="73" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="454"/>
               <rateMeasurement rate="8" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="454"/>
               <rateMeasurement rate="8" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="454"/>
               <rateMeasurement rate="4" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="454"/>
               <rateMeasurement rate="23" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="454"/>
               <rateMeasurement rate="5" sampleSize="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="452"/>
               <rateMeasurement rate="4" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="452"/>
               <rateMeasurement rate="24" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="452"/>
               <rateMeasurement rate="6" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="452"/>
               <rateMeasurement rate="20" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="452"/>
               <rateMeasurement rate="30" sampleSize="142"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="452"/>
               <rateMeasurement rate="7" sampleSize="142"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Bielski et al, 2004">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>8</value>
               <notes/>
            </centers>
            <objective>
               <value>Escitalopram is the most selective serotonin reuptake inhibitor (SRI) antidepressant available. Venlafaxine is a non-selective SRI that also inhibits noradrenergic re-uptake. This study compared escitalopram and venlafaxine extended release (XR) in depressed outpatients at the highest doses recommended in the United States.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female outpatients, 18 to 65 years of age, who met DSM-IV22 criteria for major depressive disorder were eligible for the study. Patients were required to have a minimum total score of 20 on the 24-item Hamilton Rating Scale for Depression (HAM-D)23 at both screening and baseline visits. Results of physical examinations, laboratory tests, and electrocardiograms (ECG) were required to be normal at the screening visit, or any abnormalities had to be judged clinically insignificant. Female patients of childbearing potential were required to have a negative serum β-human chorionic gonadotropin pregnancy test and to be practicing a medically accepted form of contraception.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Women who were lactating were excluded from the trial. Also excluded from the study were patients currently meeting DSM-IV criteria for primary diagnoses for any Axis I disorder other than major depressive disorder, as well as patients with a history of schizophrenia or other psychotic disorder and patients with a cognitive disorder (including mental retardation) or personality disorder of sufficient severity to interfere with their participation. Patients who met DSM-IV criteria for substance abuse or dependence within the past 6 months were ineligible to participate, as were those judged to be at risk of suicide. Patients with any clinically significant medical illness that had not been stable for at least 1 year were also excluded.

Use of a depot neuroleptic within 6 months prior to study entry was prohibited, as was use of any neuroleptic, antidepressant, or anxiolytic medication within 2 weeks (5 weeks for fluoxetine) prior to the first administration of double-blind study medication. Patients who had previously received treatment with either escitalopram or venlafaxine were not eligible to participate, nor were those who had previously failed to respond to adequate trials of 2 or more antidepressants. Concomitant use of any psychoactive drug (or any drug with a psychotropic component) was not allowed, except zolpidem or zaleplon as needed for sleep.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15367045</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="502" size="100">
               <fixedDose quantity="225.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="504" size="98">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Escitalopram"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="504"/>
               <rateMeasurement rate="59" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="504"/>
               <rateMeasurement rate="12" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="502"/>
               <rateMeasurement rate="14" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="504"/>
               <continuousMeasurement mean="-1.6" sampleSize="98" stdDev="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="502"/>
               <rateMeasurement rate="11" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="502"/>
               <rateMeasurement rate="24" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="504"/>
               <rateMeasurement rate="15" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="502"/>
               <rateMeasurement rate="17" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="502"/>
               <rateMeasurement rate="16" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="504"/>
               <rateMeasurement rate="26" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="502"/>
               <rateMeasurement rate="34" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="502"/>
               <rateMeasurement rate="12" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="504"/>
               <rateMeasurement rate="9" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="502"/>
               <continuousMeasurement mean="-1.7" sampleSize="100" stdDev="1.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="504"/>
               <rateMeasurement rate="6" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="504"/>
               <rateMeasurement rate="5" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="504"/>
               <rateMeasurement rate="2" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="502"/>
               <rateMeasurement rate="47" sampleSize="100"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Boyer et al, 1998">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>57</value>
               <notes/>
            </centers>
            <objective>
               <value>The efficacy, tolerability, quality-of-life outcomes and costs of sertraline and fluoxetine in the treatment of depression were compared in a 6-month double-blind trial in a primary-care setting in France.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>To qualify for inclusion in the study, patients had to meet DSM IV criteria for major depressive disorder, and to have a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. They were required to be outpatients, and to be between 18 and 65 years of age. Both male and female patients were eligible, although women of child-bearing age were required not to be pregnant or breastfeeding, to have been using an effective contraceptive method for at least 3 months prior to the study, and to undertake not to become pregnant during the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had concurrent major psychiatric disorders, such as anxiety disorders, dementia, somatoform disorders, agoraphobia, social phobia or obsessive-compulsive disorder, or had any history of schizophrenia, psychosis or personality disorders. Also excluded were patients with severe concurrent medical illnesses, although those with mild hypertension (untreated or stable on treatment) and mild non-insulindependent diabetes mellitus (controlled by diet or hypoglycaemic agents) were eligible. Patients with a history of thyroid disease were required to have normal thyroid function tests on entry to the study.

Other exclusion criteria included alcohol or drug dependence; a history of serious allergy or serious adverse reactions related to medicines; known allergy or hypersensitivity to lactose or fluoxetine; and previous treatment with antidepressants for less than 3 weeks, except where discontinued due to adverse effects and where the antidepressant was not fluoxetine. Patients who were considered to be at major risk of suicide were also excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10184835</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="548" size="122">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="550" size="120">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="550"/>
               <rateMeasurement rate="10" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="548"/>
               <rateMeasurement rate="63" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="550"/>
               <rateMeasurement rate="61" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="548"/>
               <rateMeasurement rate="63" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="548"/>
               <rateMeasurement rate="9" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="550"/>
               <rateMeasurement rate="61" sampleSize="120"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Burke et al, 2002">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>35</value>
               <notes/>
            </centers>
            <objective>
               <value>Escitalopram is the single isomer responsible for the serotonin reuptake inhibition produced by the racemic antidepressant citalopram. The present randomized, double-blind, placebo-controlled, fixed-dose multicenter trial was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of major depressive disorder.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible participants were male or female outpatients, 18 to 65 years of age, with DSM-IV diagnosis of major depressive disorder. Patients were required to meet DSM-IV criteria for a major depressive episode, at least 4 weeks in duration, and to have a minimum score of 22 on the Montgomery-Asberg Depression Rating Scale (MADRS), and a minimum score of 2 on item 1 (depressed mood) of the Hamilton Rating Scale for Depression (HAM-D).</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had any DSM-IV Axis I disorder other than major depression, any personality disorder, a history of substance abuse, a suicide attempt within the past year, or evidence of active suicidal ideation (as indicated by a score of at least 5 on item 10 of the MADRS). Women of childbearing potential were included only if they agreed to use a medically acceptable method of contraception; pregnant or lactating women were excluded. No concomitant psychotropic medication was permitted, except zolpidem for insomnia (no more than 3 times per week).</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12000207</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="570" size="125">
               <fixedDose quantity="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Citalopram"/>
               <notes/>
            </arm>
            <arm id="572" size="125">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Escitalopram"/>
               <notes/>
            </arm>
            <arm id="574" size="119">
               <fixedDose quantity="10.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Escitalopram"/>
               <notes/>
            </arm>
            <arm id="576" size="122">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="574"/>
               <rateMeasurement rate="59" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="576"/>
               <continuousMeasurement mean="-0.8" sampleSize="119" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="572"/>
               <continuousMeasurement mean="-1.3999999999999999" sampleSize="123" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="570"/>
               <rateMeasurement rate="13" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="572"/>
               <rateMeasurement rate="18" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="576"/>
               <rateMeasurement rate="4" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="576"/>
               <rateMeasurement rate="0" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="574"/>
               <rateMeasurement rate="25" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="574"/>
               <rateMeasurement rate="12" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="576"/>
               <rateMeasurement rate="33" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="576"/>
               <rateMeasurement rate="9" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="570"/>
               <rateMeasurement rate="57" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="576"/>
               <rateMeasurement rate="7" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="574"/>
               <rateMeasurement rate="12" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="570"/>
               <rateMeasurement rate="5" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="574"/>
               <continuousMeasurement mean="-1.3" sampleSize="118" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="570"/>
               <rateMeasurement rate="14" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="574"/>
               <rateMeasurement rate="12" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="572"/>
               <rateMeasurement rate="18" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="576"/>
               <rateMeasurement rate="9" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="572"/>
               <rateMeasurement rate="64" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="572"/>
               <rateMeasurement rate="18" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="570"/>
               <continuousMeasurement mean="-1.2" sampleSize="125" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="572"/>
               <rateMeasurement rate="11" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="572"/>
               <rateMeasurement rate="15" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="570"/>
               <rateMeasurement rate="14" sampleSize="125"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="574"/>
               <rateMeasurement rate="11" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="570"/>
               <rateMeasurement rate="28" sampleSize="125"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Chouinard et al, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>8</value>
               <notes/>
            </centers>
            <objective>
               <value>Recent studies have suggested clinical differences among selective serotonin reuptake inhibitors. In a 12-week randomized, multicenter, double-blind trial, the antidepressant and anxiolytic efficacy of the selective serotonin reuptake inhibitors paroxetine and fluoxetine was compared in patients with moderate to severe depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eight Canadian centres enrolled 203 patients (78 men, 125 women, mean age 40.9 years) who met DSM-III-R criteria for major depressive disorder following a standard clinical interview by a psychiatrist (neither the SCID nor other structured clinical interviews were used). Patients were recruited through newspaper ads and referrals. Patients were included if they had symptoms of depression for at least one month prior to the screening visit, a total score of 20 on the 21-item Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960), and a score of two on item one HAM-D at the screening visit (5–14 days prior to baseline) and at entry (Day 0).</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had significant coexisting illness, including renal, hepatic, gastrointestinal, cardiovascular or neurological disease; nonstabilized diabetes; other current Axis I psychiatric diagnosis; organic brain syndrome; past or present abuse of alcohol or illicit drugs; were at significant risk of suicide; or were pregnant or lactating. Other exclusion criteria included ECT or continuous lithium therapy in the preceding two months, mono-amine oxidase inhibitor or oral neuroleptic use in the preceding 21 days, any antidepressant or sedative hypnotic (except chloral hydrate) in the previous seven days, fluoxetine in the previous 35 days, or current therapy with an anticoagulant or type 1C antiarrhythmic (e.g. flecainide, propafenone). Patients who had clinically significant abnormalities on the prestudy physical examination, ECG or laboratory tests (hematology, biochemistry and thyroid tests) were also excluded. The use of formal psychotherapy was not permitted for the duration of the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10403145</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Impotence">
               <adverseEvent name="Impotence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Respiratory Disorder">
               <adverseEvent name="Respiratory Disorder"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="640" size="102">
               <flexibleDose minDose="20.0" maxDose="50.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="642" size="101">
               <flexibleDose minDose="20.0" maxDose="80.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="640"/>
               <rateMeasurement rate="25" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="640"/>
               <rateMeasurement rate="12" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="642"/>
               <rateMeasurement rate="10" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="642"/>
               <rateMeasurement rate="17" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="642"/>
               <rateMeasurement rate="37" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="640"/>
               <rateMeasurement rate="13" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="640"/>
               <rateMeasurement rate="38" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="642"/>
               <rateMeasurement rate="7" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="640"/>
               <rateMeasurement rate="13" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Respiratory Disorder"/>
               <arm id="642"/>
               <rateMeasurement rate="9" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="642"/>
               <continuousMeasurement mean="-1.8" sampleSize="101" stdDev="0.16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="642"/>
               <rateMeasurement rate="33" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="640"/>
               <rateMeasurement rate="19" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="642"/>
               <rateMeasurement rate="3" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="640"/>
               <rateMeasurement rate="37" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="642"/>
               <rateMeasurement rate="32" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="640"/>
               <rateMeasurement rate="18" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="640"/>
               <rateMeasurement rate="14" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="640"/>
               <rateMeasurement rate="14" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="640"/>
               <rateMeasurement rate="40" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="642"/>
               <rateMeasurement rate="6" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="640"/>
               <continuousMeasurement mean="-0.6899999999999999" sampleSize="102" stdDev="0.16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="642"/>
               <rateMeasurement rate="67" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="640"/>
               <rateMeasurement rate="4" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="642"/>
               <rateMeasurement rate="23" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Respiratory Disorder"/>
               <arm id="640"/>
               <rateMeasurement rate="13" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="642"/>
               <rateMeasurement rate="19" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="642"/>
               <rateMeasurement rate="6" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="640"/>
               <rateMeasurement rate="15" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="640"/>
               <rateMeasurement rate="27" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="642"/>
               <rateMeasurement rate="4" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="642"/>
               <rateMeasurement rate="16" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="640"/>
               <rateMeasurement rate="67" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="640"/>
               <rateMeasurement rate="14" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="642"/>
               <rateMeasurement rate="12" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="640"/>
               <rateMeasurement rate="12" sampleSize="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="642"/>
               <rateMeasurement rate="17" sampleSize="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="642"/>
               <rateMeasurement rate="10" sampleSize="101"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Coleman et al, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>This study compared the sexual functioning effects as well as the safety and efficacy of bupropion sustained release (bupropion SR) and sertraline.
</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women at least 18 years of age were eligible for the study if they had a diagnosis of moderate to severe depression based on DSM-IV criteria and a minimum score of 18 on the first 21 items of the 31-item Hamilton Rating Scale for Depression (HAM-D) at screening (day -6) and baseline (day 0), and were currently experiencing a recurrent major depressive episode with a duration of 2 to 24 months. Patients were required to be in a stable relationship, have normal sexual functioning and sexual activity that could lead to orgasm at least once every 2 weeks, and be willing to discuss their sexual functioning with the investigator. Normal sexual functioning was defined as the absence of sexual arousal disorder, orgasm dysfunction, premature ejaculation, dyspareunia, and vaginismus. Because lack of sexual desire is common in some patients with underlying depression (26), patients with sexual desire disorder were eligible for the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the study if they had a known predisposition to seizure or were receiving medications that lower the seizure threshold; had a history or current diagnosis of anorexia or bulimia; were pregnant or lactating, or did not agree to avoid pregnancy during the study; had a history of alcohol or substance abuse within the past year; had used any psychoactive drug within 1 week of study drug treatment (2 weeks for monoamine oxidase inhibitors or protriptyline, 4 weeks for fluoxetine or any investigational drug); had a history of prior treatment with bupropion or sertraline; or were actively suicidal.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10596735</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Rhinitis">
               <adverseEvent name="Rhinitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="726" size="118">
               <flexibleDose minDose="50.0" maxDose="200.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="728" size="122">
               <flexibleDose minDose="150.0" maxDose="400.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Bupropion"/>
               <notes/>
            </arm>
            <arm id="730" size="124">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="726"/>
               <rateMeasurement rate="11" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="728"/>
               <rateMeasurement rate="21" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="728"/>
               <rateMeasurement rate="14" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="728"/>
               <rateMeasurement rate="14" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="728"/>
               <rateMeasurement rate="81" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="730"/>
               <rateMeasurement rate="69" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="730"/>
               <rateMeasurement rate="8" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="726"/>
               <rateMeasurement rate="20" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="730"/>
               <rateMeasurement rate="40" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="728"/>
               <rateMeasurement rate="24" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="726"/>
               <rateMeasurement rate="6" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="726"/>
               <rateMeasurement rate="31" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="730"/>
               <rateMeasurement rate="19" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="726"/>
               <rateMeasurement rate="19" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="728"/>
               <rateMeasurement rate="23" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="726"/>
               <rateMeasurement rate="26" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="730"/>
               <rateMeasurement rate="14" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="730"/>
               <rateMeasurement rate="17" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="730"/>
               <rateMeasurement rate="32" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="726"/>
               <rateMeasurement rate="14" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="730"/>
               <rateMeasurement rate="4" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="728"/>
               <rateMeasurement rate="9" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="728"/>
               <rateMeasurement rate="27" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="730"/>
               <rateMeasurement rate="8" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="730"/>
               <rateMeasurement rate="11" sampleSize="124"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="726"/>
               <rateMeasurement rate="72" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="726"/>
               <rateMeasurement rate="43" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="728"/>
               <rateMeasurement rate="9" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="728"/>
               <rateMeasurement rate="40" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="726"/>
               <rateMeasurement rate="21" sampleSize="118"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Coleman et al, 2001">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>Many antidepressants are associated with sexual dysfunction, a side effect that may lead to patients’ dissatisfaction and noncompliance with treatment.

This study compared the efficacy, tolerability, and effects on sexual functioning of bupropion sustained release (bupropion SR) and the selective serotonin reuptake inhibitor fluoxetine.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible patients were men and women aged &gt;= 18 years with a diagnosis of moderate to severe depression (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-ZV] criteria and a minimum score of 20 on the 21-item Hamilton Rating Scale for Depression [HAM-D] at screening [day -7] and baseline [day -1]) who were currently experiencing an episode of recurrent major depression lasting from 2 to 24 months. Patients were required to be involved in sexual activity (in a stable relationship or through masturbation) that had the potential to lead to orgasm on &gt;= 1 occasion every 2 weeks. They were also required to have normal sexual functioning, defined as the absence of sexual arousal disorder (erectile difficulties in men and lubrication or swelling difficulties in women), orgasm dysfunction (delay or failure to achieve orgasm), premature ejaculation, dyspareunia, or vaginismus. Patients had to be willing to
discuss their sexual functioning with an investigator or the investigator's designee. Because decreased sexual desire is common in depression, patients with sexual desire disorder (deficiency of sexual fantasies and desire for sexual activity) were eligible for the study as long as they were having sexual activity on &gt;= 1 occasion every 2 weeks.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the study if they had received treatment with bupropion or fluoxetine within the past year; had not responded to antidepressant treatment for a previous depressive episode; were actively suicidal; had a known predisposition to seizures or were receiving medications that lowered the seizure threshold; had a history or current diagnosis of anorexia or bulimia; were pregnant or lactating, or did not agree to avoid pregnancy during the study; had a history of alcohol or substance abuse within the past year; or had used any psychoactive drug within 1 week of treatment with study drug (2 weeks for monoamine oxidase inhibitors or protriptyline, 4 weeks for any investigational drug).</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>11519769</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction">
               <adverseEvent name="Orgasmic Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="798" size="154">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="800" size="150">
               <flexibleDose minDose="150.0" maxDose="400.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Bupropion"/>
               <notes/>
            </arm>
            <arm id="802" size="152">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="800"/>
               <rateMeasurement rate="4" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="802"/>
               <rateMeasurement rate="15" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="798"/>
               <rateMeasurement rate="15" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="798"/>
               <rateMeasurement rate="18" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="800"/>
               <rateMeasurement rate="14" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="802"/>
               <rateMeasurement rate="50" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="798"/>
               <rateMeasurement rate="16" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="798"/>
               <rateMeasurement rate="22" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="800"/>
               <rateMeasurement rate="44" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="798"/>
               <rateMeasurement rate="88" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="802"/>
               <rateMeasurement rate="31" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="802"/>
               <rateMeasurement rate="22" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="800"/>
               <rateMeasurement rate="21" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="798"/>
               <rateMeasurement rate="57" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="800"/>
               <rateMeasurement rate="56" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="802"/>
               <rateMeasurement rate="10" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="798"/>
               <rateMeasurement rate="44" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="800"/>
               <rateMeasurement rate="42" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="800"/>
               <rateMeasurement rate="84" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="798"/>
               <rateMeasurement rate="17" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="800"/>
               <rateMeasurement rate="13" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="802"/>
               <rateMeasurement rate="76" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="802"/>
               <rateMeasurement rate="13" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="800"/>
               <rateMeasurement rate="17" sampleSize="150"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="802"/>
               <rateMeasurement rate="21" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="802"/>
               <rateMeasurement rate="24" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="798"/>
               <rateMeasurement rate="47" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="802"/>
               <rateMeasurement rate="6" sampleSize="152"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="798"/>
               <rateMeasurement rate="18" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="800"/>
               <rateMeasurement rate="32" sampleSize="150"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Croft et al, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>8</value>
               <notes/>
            </centers>
            <objective>
               <value>Sexual dysfunction, a frequently reported side effect of many antidepressants, may result in patient dissatisfaction and noncompliance with treatment regimens. This paper describes the results of the first placebo-controlled comparisonof the efficacy, safety, and effects on sexual functioning of sustained-release bupropion (bupropion SR) and the selective serotonin reuptake inhibitor sertraline.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women 2 18 years of age were eligible for the study if they had a diagnosis of moderate-to-severe depression (basedon Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IVJ criteria and a scoreof &gt;= 18 on the first 21 items of the 31-item Hamilton Rating Scale for Depression [HAM-D]) at screening (day -6) and baseline (day 0) and were currently experiencing a recurrent major depressive episode of 8 weeks' to 24 months' duration. They were also required to be in a stable relationship, have normal sexual functioning and sexual activity that could lead to orgasm at least once every 2 weeks, and be willing to discusstheir sexual functioning with the investigator. Normal sexual functioning was defined as the absence of sexual arousal disorder, orgasmic dysfunction, premature ejaculation, dyspareunia, and vaginismus. Becauselack of sexual desire is common in some patients with underlying depression, patients with sexual desire disorder were considered eligible for the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the study if they had a known predisposition to seizures or were receiving medications that lower the seizure threshold; had a history or current diagnosis of anorexia or bulimia; were pregnant or lactating or did not agree to avoid pregnancy during the study; had a history of alcohol or substance abuse within the past year; had used any psychoactive drug within 1 week of study treatment (2 weeks for monoamine oxidase inhibitors or protriptyline, 4 weeks for fluoxetine or any investigational drug); had a history of treatment with bupropion or sertraline; or were actively suicidal.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10363731</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction">
               <adverseEvent name="Orgasmic Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="870" size="119">
               <flexibleDose minDose="50.0" maxDose="200.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="872" size="120">
               <flexibleDose minDose="150.0" maxDose="400.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Bupropion"/>
               <notes/>
            </arm>
            <arm id="874" size="121">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="870"/>
               <rateMeasurement rate="21" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="872"/>
               <rateMeasurement rate="21" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="870"/>
               <rateMeasurement rate="81" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="872"/>
               <rateMeasurement rate="36" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="872"/>
               <rateMeasurement rate="79" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="872"/>
               <rateMeasurement rate="22" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="872"/>
               <rateMeasurement rate="8" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="874"/>
               <rateMeasurement rate="5" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="874"/>
               <rateMeasurement rate="12" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="874"/>
               <rateMeasurement rate="41" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="874"/>
               <rateMeasurement rate="10" sampleSize="116"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="874"/>
               <rateMeasurement rate="57" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="870"/>
               <rateMeasurement rate="31" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="870"/>
               <rateMeasurement rate="47" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="870"/>
               <rateMeasurement rate="20" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="872"/>
               <rateMeasurement rate="4" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="874"/>
               <rateMeasurement rate="36" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="872"/>
               <rateMeasurement rate="18" sampleSize="116"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="874"/>
               <rateMeasurement rate="13" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="874"/>
               <rateMeasurement rate="7" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="874"/>
               <rateMeasurement rate="14" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="870"/>
               <rateMeasurement rate="16" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="870"/>
               <rateMeasurement rate="37" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="870"/>
               <rateMeasurement rate="39" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="872"/>
               <rateMeasurement rate="15" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="872"/>
               <rateMeasurement rate="40" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgasmic Dysfunction"/>
               <arm id="870"/>
               <rateMeasurement rate="48" sampleSize="119"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Dalery and Honig, 2003">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Fluvoxamine versus fluoxetine in major depressive episodes: a double-blind randomised comparison</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>24</value>
               <notes/>
            </centers>
            <objective>
               <value>To compare the efficacy and safety of fluvoxamine and fluoxetine in outpatients with major depressive episode.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Outpatients of either sex, aged 18–70 years old, meeting DSM-III-R criteria for major depressive episode and having a total score of 17 or more on the 17-item Hamilton depression rating scale (HAMD) were included in the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had: acute suicidal ideation or a serious suicide attempt in the previous 6 months; dementia; a history of epilepsy or seizures; concurrent or recent (6 months) alcoholism, other psychoactive substance abuse or drug-induced psychosis; were pregnant, lactating or of childbearing potential and not taking adequate contraceptive measures; or if they had clinically uncontrolled hepatic, renal, pulmonary, endocrine or collagen disease. Also excluded were patients who had previously failed SSRI therapy or who required concomitant lithium, warfarin, hepatically metabolised antivitamin K agents, carbamazepine, theophylline, insulin or hypoglycaemic agents. Patients were required not to receive monoamine oxidase inhibitors or electroconvulsive therapy (ECT) in the 2 weeks prior to the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12858325</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="936" size="90">
               <fixedDose quantity="100.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluvoxamine"/>
               <notes/>
            </arm>
            <arm id="938" size="94">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="936"/>
               <rateMeasurement rate="13" sampleSize="90"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="938"/>
               <rateMeasurement rate="10" sampleSize="94"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="936"/>
               <rateMeasurement rate="2" sampleSize="90"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="938"/>
               <rateMeasurement rate="20" sampleSize="94"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="936"/>
               <rateMeasurement rate="54" sampleSize="90"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="938"/>
               <rateMeasurement rate="14" sampleSize="94"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="938"/>
               <rateMeasurement rate="56" sampleSize="94"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="936"/>
               <rateMeasurement rate="16" sampleSize="90"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="De Nayer et al, 2002">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>The aim of this double-blind study was to compare the efficacy and safety of venlafaxine vs. fluoxetine in the treatment of patients with depression and anxiety.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female patients between the ages of 18 and 70 yr inclusive, who had provided written informed consent, were enrolled. Patients were required to have a baseline score between 18 and 25, inclusive, on the 21-item HAMD Scale, as well as a minimum baseline score of 8 on the Covi Anxiety Scale, and to be considered by the investigator to be moderately depressed. Females of childbearing potential were required to have a negative pregnancy test at baseline, and to use a medically acceptable form of contraception throughout the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Pregnant or breast-feeding patients were not enrolled into the study ; neither were patients with concomitant psychiatric disease or personality disorder, or known clinically significant laboratory abnormalities. Patients were also excluded if they had used any other investigational or antipsychotic drug or electroconvulsive therapy (ECT) within 30d of baseline. Prohibited medications included fluoxetine within 21 dof baseline, MAO inhibitors within 14d of baseline, antidepressants, other psychotropic drugs, or non-psychotropic drugs with psychotropic effects in the 7d before baseline (unless the dose had been stable for at least 1 month). Anxiolytic drugs (including lorazepam), antidepressants other than the study medication, ECT, investigational drugs, and other psychopharmacological drugs were prohibited during the study. Patients were, however, permitted to take 2 mg lormetazepam at bedtime, if required for sleep, as well as other medication to treat inter-current medical conditions, at the discretion of the investigator. Patients who had previously failed to respond to venlafaxine or fluoxetine treatment, or who were acutely suicidal were not enrolled into the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12135535</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="962" size="73">
               <flexibleDose minDose="75.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="964" size="73">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="964"/>
               <rateMeasurement rate="16" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="964"/>
               <rateMeasurement rate="8" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="962"/>
               <rateMeasurement rate="37" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="962"/>
               <rateMeasurement rate="6" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="964"/>
               <rateMeasurement rate="29" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="962"/>
               <rateMeasurement rate="21" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="962"/>
               <rateMeasurement rate="24" sampleSize="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="964"/>
               <rateMeasurement rate="27" sampleSize="73"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="De Wilde et al, 1993">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>To compare the efficacy and tolerability of once or twice daily administration of paroxetine and fluoxetine.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients of either sex were eligible for entry to a 1-week placebo run-in phase if they were aged 18-65 years, diagnosed with major depression according to the DSM-III criteria, with a score of 18 or more on the HAM-D scale and if they had given informed consent.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>The following patients were excluded: pregnant or lactating women, patients with severe concomitant disease, schizophrenics, known abusers of alcohol or illicit drugs and patients with severe risk of suicide; those who had received electroconvulsive therapy in the previous 3 months, monoamine oxidase inhibitors or oral neuroleptics in the previous 14 days, depot neuroleptics in the previous 4 weeks and patients receiving lithium were also excluded.

Patients whose HAM-D score at baseline was improved by more than 20%, or was less than 18, were excluded from participating in the active phase of the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>8447241</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="988" size="37">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="990" size="41">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="988"/>
               <rateMeasurement rate="1" sampleSize="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="988"/>
               <rateMeasurement rate="25" sampleSize="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="988"/>
               <rateMeasurement rate="8" sampleSize="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="988"/>
               <rateMeasurement rate="24" sampleSize="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="990"/>
               <rateMeasurement rate="7" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="990"/>
               <rateMeasurement rate="13" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="990"/>
               <rateMeasurement rate="26" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="990"/>
               <rateMeasurement rate="10" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="988"/>
               <rateMeasurement rate="10" sampleSize="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="988"/>
               <rateMeasurement rate="10" sampleSize="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="990"/>
               <rateMeasurement rate="10" sampleSize="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="990"/>
               <rateMeasurement rate="25" sampleSize="41"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Detke et al, 2004">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Duloxetine in the accute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE) that has previously been shown to be effective in the acute treatment of major depressive disorder (MDD). This placebo-controlled study assesses the safety and efficacy of duloxetine (80 or 120 mg/day) and paroxetine (20 mg QD) during an initial 8-week acute phase and subsequent 6-month continuation phase treatment of MDD.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients were at least 18 years of age and met criteria for MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). The diagnosis of MDD was confirmed by the Mini International Neuropsychiatric Interview (MINI). In addition, patients had both a Clinical Global Impression of Severity (CGI-Severity) rating &gt;= 4 (moderate) and a clinician-rated HAMD17 total score &gt;= 15 at the screening and baseline study visits. </value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had any current primary DSM-IV Axis I diagnosis other than MDD or any anxiety disorder as a primary diagnosis within the year preceding enrollment; any previous diagnosis of bipolar disorder, psychosis, or schizoaffective disorder; a history of substance abuse or dependence within the past year or a positive urine drug screen; a lack of response to at least two adequate courses of antidepressant therapy (at least 4 weeks duration) within the therapeutic dose range during their current MDD episode; serious suicidal risk; or a serious medical illness (cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality). Patients were permitted to take nonprescription, but not prescription, analgesic medications. Patients were not selected for the presence, type, or severity of pain.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15589385</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1022" size="86">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="1024" size="93">
               <fixedDose quantity="120.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Duloxetine"/>
               <notes/>
            </arm>
            <arm id="1026" size="95">
               <fixedDose quantity="80.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Duloxetine"/>
               <notes/>
            </arm>
            <arm id="1028" size="93">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1028"/>
               <rateMeasurement rate="6" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1022"/>
               <rateMeasurement rate="64" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1026"/>
               <rateMeasurement rate="3" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1028"/>
               <rateMeasurement rate="0" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1024"/>
               <rateMeasurement rate="5" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1026"/>
               <rateMeasurement rate="12" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1024"/>
               <rateMeasurement rate="66" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1026"/>
               <rateMeasurement rate="12" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1024"/>
               <rateMeasurement rate="15" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1022"/>
               <rateMeasurement rate="6" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1024"/>
               <rateMeasurement rate="9" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1022"/>
               <continuousMeasurement mean="-2.1" sampleSize="85" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1028"/>
               <rateMeasurement rate="2" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1026"/>
               <continuousMeasurement mean="-2.0" sampleSize="95" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1026"/>
               <rateMeasurement rate="4" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1028"/>
               <rateMeasurement rate="18" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1024"/>
               <rateMeasurement rate="8" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1024"/>
               <rateMeasurement rate="8" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1024"/>
               <rateMeasurement rate="5" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1026"/>
               <rateMeasurement rate="5" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1028"/>
               <rateMeasurement rate="0" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1022"/>
               <rateMeasurement rate="6" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1026"/>
               <rateMeasurement rate="12" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1024"/>
               <rateMeasurement rate="5" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1028"/>
               <continuousMeasurement mean="-1.5" sampleSize="93" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1028"/>
               <rateMeasurement rate="12" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1024"/>
               <rateMeasurement rate="7" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1022"/>
               <rateMeasurement rate="4" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1024"/>
               <continuousMeasurement mean="-2.2" sampleSize="93" stdDev="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1022"/>
               <rateMeasurement rate="3" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1022"/>
               <rateMeasurement rate="10" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1028"/>
               <rateMeasurement rate="7" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1028"/>
               <rateMeasurement rate="41" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1022"/>
               <rateMeasurement rate="5" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1026"/>
               <rateMeasurement rate="2" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1022"/>
               <rateMeasurement rate="5" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1028"/>
               <rateMeasurement rate="0" sampleSize="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1022"/>
               <rateMeasurement rate="10" sampleSize="86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1026"/>
               <rateMeasurement rate="62" sampleSize="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1026"/>
               <rateMeasurement rate="5" sampleSize="95"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Dierick et al, 1996">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>Comparison of the efficacy and safety of venlafaxine and fluoxetine in outpatients with major depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and nonpregnant women practicing adequate birth control were eligible if they were in good general physical health; met the DSM-III R criteria for a major depressive episode; had a minimum baseline score of 20 on the 21-item Hamilton Depression Rating Scale (HAM-D) with not more than a 20% decrease in score between screening and baseline; and were able to be treated on an outpatient basis.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if the following conditions were met: a history of clinically significant physical disease or clinically significant abnormalities on a screening physical examination, electrocardiogram (ECG), or laboratory tests; acute suicidal tendencies; a history of a seizure disorder; presence of an organic mental disorder, bipolar depression, or a serious personality disorder; a history of any psychotic disorder not associated with depression; venlafaxine fluoxetine hypersensitivity or or use within two months of baseline; use of any investigational drug, antipsychotic drug, monoamine oxidase inhibitor, or electroconvulsive therapy within 14 days of baseline; use of any antidepressant drug within seven days of baseline; use of any anxiolytic that could not be withdrawn before baseline; use of any non-psychotropic drug with psychotropic effects (eg, beta-adrenergic blockers), unless the dosage had been stable for a minimum of one month prior to double-blind treatment; or a history of drug or alcohol abuse within two years of the start of the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>8861177</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Palpitation">
               <adverseEvent name="Palpitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1116" size="153">
               <flexibleDose minDose="75.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="1118" size="161">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1118"/>
               <rateMeasurement rate="95" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1118"/>
               <rateMeasurement rate="23" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1116"/>
               <rateMeasurement rate="38" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1116"/>
               <rateMeasurement rate="9" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1118"/>
               <rateMeasurement rate="20" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="1116"/>
               <rateMeasurement rate="7" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1116"/>
               <rateMeasurement rate="7" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1116"/>
               <rateMeasurement rate="15" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1118"/>
               <rateMeasurement rate="8" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1118"/>
               <rateMeasurement rate="11" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1116"/>
               <rateMeasurement rate="15" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1118"/>
               <rateMeasurement rate="13" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1118"/>
               <rateMeasurement rate="40" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1118"/>
               <rateMeasurement rate="7" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1116"/>
               <rateMeasurement rate="43" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1116"/>
               <rateMeasurement rate="11" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1116"/>
               <rateMeasurement rate="107" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1118"/>
               <rateMeasurement rate="3" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1116"/>
               <rateMeasurement rate="7" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1118"/>
               <rateMeasurement rate="7" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1116"/>
               <rateMeasurement rate="6" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1116"/>
               <rateMeasurement rate="9" sampleSize="153"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="1118"/>
               <rateMeasurement rate="2" sampleSize="161"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1118"/>
               <rateMeasurement rate="8" sampleSize="161"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Ekselius et al, 1997">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>39</value>
               <notes/>
            </centers>
            <objective>
               <value>The purpose of this double-blind, multicenter trial was to compare the efficacy and safety of sertraline (50-150 mg/day) with those of citalopram (20-60 mg/day) in patients with major depression in general practice during 24 weeks of treatment.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female patients, between the ages of 18 and 70 years, who had given signed informed consent to participate and who fulfilled the DSM-III-R criteria for major depression of a severity corresponding to a MADSR total score of at least 21, entered the trial. The MADRS score should not be reduced by more than 25% from the time of first assessment to inclusion.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Women were excluded from the study if they were pregnant, lactating, or sexually active and of childbearing potential without using an adequate method of contraception. Patients were also excluded if they had any of the following: severe depression of psychotic dimension; previous history of serious suicide attempt or suicide risk; therapy refractory depression (i.e. 8 weeks or more of treatment with antidepressants in this episode without significant effect or duration of current episode &gt; 1 year); previous treatment with sertraline or citalopram without significant effect; bipolar disorder; previous or present history of alcohol or drug abuse; history of epilepsy; known intolerance or allergic reactions to SSRIs; therapy with lithium within the preceding month; currently receiving and unable to discontinue any other psychotropic medication, except for a hypnotic for insomnia or a daytime anxiolytic (nitrazepam 2.5-10 mg/day, flunitrazepam 0.5-2 mg/day or oxazepam 15-25 mg/day); currently receiving treatment with cimetidine, warfarin or tryptophan; or significant concomitant hepatic or renal diseas. Other reasons for exclusion were previous participation in the study; participation in a clinical study involving investigation or marketed products within 1 month before the study; and donating blood during or for 2 weeks after the completion of the study, or both. Additionally, patients considered by the investigators to invalidate informed consent or limit compliance with protocol requirements were not permitted to enter the study. Patients who had been receiving antidepressant drugs were required to have a washout period of at least 3 weeks before inclusion.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>9547134</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Erectile Dysfunction">
               <adverseEvent name="Erectile Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Concentration Difficulties">
               <adverseEvent name="Concentration Difficulties"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Palpitation">
               <adverseEvent name="Palpitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dream Abnormality">
               <adverseEvent name="Dream Abnormality"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Reduced Sleep">
               <adverseEvent name="Reduced Sleep"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Orgiastic Dysfunction">
               <adverseEvent name="Orgiastic Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Rash">
               <adverseEvent name="Rash"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Failing Memory">
               <adverseEvent name="Failing Memory"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Loss">
               <adverseEvent name="Weight Loss"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire">
               <adverseEvent name="Diminished Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Micturation Disturbances">
               <adverseEvent name="Micturation Disturbances"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Increased Sexual Desire">
               <adverseEvent name="Increased Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Emotional Indifference">
               <adverseEvent name="Emotional Indifference"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Gain">
               <adverseEvent name="Weight Gain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Reduced Salivation">
               <adverseEvent name="Reduced Salivation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Increased Salivation">
               <adverseEvent name="Increased Salivation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1174" size="200">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Citalopram"/>
               <notes/>
            </arm>
            <arm id="1176" size="200">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="1174"/>
               <rateMeasurement rate="19" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1176"/>
               <rateMeasurement rate="52" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1174"/>
               <rateMeasurement rate="35" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Concentration Difficulties"/>
               <arm id="1174"/>
               <rateMeasurement rate="1" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="1174"/>
               <rateMeasurement rate="162" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Reduced Sleep"/>
               <arm id="1176"/>
               <rateMeasurement rate="7" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Emotional Indifference"/>
               <arm id="1176"/>
               <rateMeasurement rate="1" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Failing Memory"/>
               <arm id="1176"/>
               <rateMeasurement rate="4" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Concentration Difficulties"/>
               <arm id="1176"/>
               <rateMeasurement rate="2" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1174"/>
               <rateMeasurement rate="9" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rash"/>
               <arm id="1174"/>
               <rateMeasurement rate="6" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1176"/>
               <rateMeasurement rate="6" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Emotional Indifference"/>
               <arm id="1174"/>
               <rateMeasurement rate="2" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1174"/>
               <rateMeasurement rate="5" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Increased Sexual Desire"/>
               <arm id="1176"/>
               <rateMeasurement rate="7" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1176"/>
               <rateMeasurement rate="19" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1176"/>
               <rateMeasurement rate="8" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rash"/>
               <arm id="1176"/>
               <rateMeasurement rate="5" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1174"/>
               <rateMeasurement rate="13" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Micturation Disturbances"/>
               <arm id="1176"/>
               <rateMeasurement rate="4" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1174"/>
               <rateMeasurement rate="10" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Erectile Dysfunction"/>
               <arm id="1174"/>
               <rateMeasurement rate="7" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Increased Salivation"/>
               <arm id="1176"/>
               <rateMeasurement rate="0" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1176"/>
               <rateMeasurement rate="12" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1176"/>
               <rateMeasurement rate="26" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1176"/>
               <rateMeasurement rate="13" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgiastic Dysfunction"/>
               <arm id="1174"/>
               <rateMeasurement rate="24" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Micturation Disturbances"/>
               <arm id="1174"/>
               <rateMeasurement rate="6" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1176"/>
               <rateMeasurement rate="10" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Orgiastic Dysfunction"/>
               <arm id="1176"/>
               <rateMeasurement rate="13" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1176"/>
               <rateMeasurement rate="14" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Erectile Dysfunction"/>
               <arm id="1176"/>
               <rateMeasurement rate="3" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1174"/>
               <rateMeasurement rate="14" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1174"/>
               <continuousMeasurement mean="-2.8999999999999999" sampleSize="200" stdDev="0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1174"/>
               <rateMeasurement rate="7" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="1174"/>
               <rateMeasurement rate="8" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Reduced Sleep"/>
               <arm id="1174"/>
               <rateMeasurement rate="12" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1176"/>
               <rateMeasurement rate="17" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="1176"/>
               <rateMeasurement rate="30" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1176"/>
               <rateMeasurement rate="18" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1174"/>
               <rateMeasurement rate="3" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1174"/>
               <rateMeasurement rate="4" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="1176"/>
               <rateMeasurement rate="151" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1174"/>
               <rateMeasurement rate="36" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1174"/>
               <rateMeasurement rate="16" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="1174"/>
               <rateMeasurement rate="26" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1176"/>
               <continuousMeasurement mean="-2.8999999999999999" sampleSize="200" stdDev="0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Increased Salivation"/>
               <arm id="1174"/>
               <rateMeasurement rate="1" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="1176"/>
               <rateMeasurement rate="9" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1176"/>
               <rateMeasurement rate="6" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1174"/>
               <rateMeasurement rate="13" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Reduced Salivation"/>
               <arm id="1176"/>
               <rateMeasurement rate="24" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1176"/>
               <rateMeasurement rate="6" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1174"/>
               <rateMeasurement rate="34" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1176"/>
               <rateMeasurement rate="25" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Increased Sexual Desire"/>
               <arm id="1174"/>
               <rateMeasurement rate="14" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="1176"/>
               <rateMeasurement rate="6" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Reduced Salivation"/>
               <arm id="1174"/>
               <rateMeasurement rate="16" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1174"/>
               <rateMeasurement rate="11" sampleSize="200"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Failing Memory"/>
               <arm id="1174"/>
               <rateMeasurement rate="7" sampleSize="200"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Fava et al, 1998">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>5</value>
               <notes/>
            </centers>
            <objective>
               <value>Comparison of the efficacy and tolerability of paroxetine and fluoxetine in outpatients with major depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Outpatients with moderate to moderately severe major depression without a history of mania or hypomania were recruited between 1993 and 1994. For each subject, a Raskin Depression Scale score of at least 8, and larger in value than the Covi Anxiety Scale score was required, as well as a Hamilton Rating Scale for Depression (HAM-D) score of 18 or greater on the first 17 items.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Excluded were patients with the following primary psychiatric diagnoses: schizophrenia, adjustment disorder, bipolar disorder, panic disorder, social phobia, obsessive-compulsive disorder, psychotic depression, and atypical depression. Other exclusions included patients whose HAM-D total score fell by 25% or more between the screen and baseline evaluations, patients with serious concomitant medical illness or significant abnormal laboratory values at screening or baseline, patients with history of seizure disorders (except febrile seizures in childhood), patients judged to have a high suicidal risk by the investigator, patients with a recent history (within 6 months) of alcohol or drug abuse, patients who required therapy with other psychotropic drug within 14 days of baseline (with the exception of chloral hydrate for sleep), patients who received electroconvulsive therapy within 3 months of baseline, were hypersensitive to fluoxetine during a prior treatment period, or used any investigational drug within 30 days of baseline, and patients previously treated with paroxetine. Women of childbearing age were excluded if they had positive pregnancy tests or did not practice medically accepted means of birth control. 

Screening included pregnancy testing for women, body weight determination, medical history, physical examination, 12-lead ECG, vital signs (including screen for postural hypotension), laboratory testing, including: hematology (hematocrit, hemoglobin, WBC with differential, platelet count); blood chemistry (alkaline phosphatase, BUN, creatinine, AST, ALT, total bilirubin, total T3, and total T4); and urinalysis (if dipstick was positive for blood or protein, full microscopy was performed). Psychiatric screening included: DSM-III-R multi-axial diagnostic evaluations, 21-item HAM-D, Raskin Depression Scale, Covi Anxiety Scale, and a detailed psychiatric history.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>9988054</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction">
               <adverseEvent name="Sexual Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1304" size="55">
               <flexibleDose minDose="20.0" maxDose="50.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="1306" size="54">
               <flexibleDose minDose="20.0" maxDose="80.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="1308" size="19">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1308"/>
               <rateMeasurement rate="10" sampleSize="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction"/>
               <arm id="1304"/>
               <rateMeasurement rate="14" sampleSize="55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1306"/>
               <rateMeasurement rate="31" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1304"/>
               <rateMeasurement rate="32" sampleSize="55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1308"/>
               <rateMeasurement rate="5" sampleSize="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1306"/>
               <rateMeasurement rate="11" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1308"/>
               <rateMeasurement rate="4" sampleSize="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1304"/>
               <rateMeasurement rate="14" sampleSize="55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1304"/>
               <rateMeasurement rate="16" sampleSize="55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1306"/>
               <rateMeasurement rate="16" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1308"/>
               <rateMeasurement rate="2" sampleSize="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction"/>
               <arm id="1308"/>
               <rateMeasurement rate="0" sampleSize="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1306"/>
               <rateMeasurement rate="23" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction"/>
               <arm id="1306"/>
               <rateMeasurement rate="4" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1304"/>
               <rateMeasurement rate="16" sampleSize="55"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Fava et al, 2002">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Accute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>15</value>
               <notes/>
            </centers>
            <objective>
               <value>This study assessed whether fluoxetine, sertraline, and paroxetine differ in efficacy and tolerability in depressed patients and the impact of baseline insomnia on outcomes. 
</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The study population included male and female outpatients, at least 18 years old, who, for at least 1 month, met the DSM-V criteria for major depressive disorder or atypical major depressive disorder using the DSM-IV, as assessed by the Structured Clinical Interview for DSM-IV. Patients were required to exhibit a baseline score of more than 16 on the first 17 items (HAM-D-17) of the 28-item HAM-D (HAM-D-28). Patients were primarily recruited from general advertising and clinician referrals.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the study for any of the following reasons: pregnant or lactating women or women of childbearing potential not using a medically accepted means of contraception; serious suicidal risk; serious comorbid illness that was not stabilized; presence of a seizure disorder with a seizure occurring within the past year; presence of any of the following DSM-IV diagnoses: organic mental disorder, substance-use disorder, schizophrenia, delusional disorder, psychotic disorders not elsewhere classified, bipolar disorder, and antisocial personality disorder; mood-congruent or mood-incongruent psychotic features; history of allergy to the study drugs or history of multiple adverse drug reactions; concomitant use of any antidepressant (other than study drugs), anxiolytic, or
other psychotropic medication within 7 days before study entry, with the exception of chloral hydrate; use of monoamine oxidase inhibitors (MAOIs) within 2 weeks of active therapy or anticipated need to use an MAOI within 5 weeks of discontinuing the study; hyper- or hypo-thyroidism (thyroid replacement was allowed, and patients were allowed to enter if they were clinically and biochemically euthyroid); and lack of response to treatment of current major depression episode by any SSRI, defined as 6 weeks or more of treatment with 40 mg or more per day fluoxetine, 150 mg or more per day of sertraline, or 40 mg or more per day of paroxetine.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>11910258</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Impotence">
               <adverseEvent name="Impotence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Rhinitis">
               <adverseEvent name="Rhinitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dream Abnormality">
               <adverseEvent name="Dream Abnormality"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Chest Pain">
               <adverseEvent name="Chest Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire">
               <adverseEvent name="Diminished Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1346" size="96">
               <flexibleDose minDose="50.0" maxDose="200.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="1348" size="96">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="1350" size="92">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1350"/>
               <rateMeasurement rate="8" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1346"/>
               <rateMeasurement rate="25" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Chest Pain"/>
               <arm id="1348"/>
               <rateMeasurement rate="5" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1346"/>
               <rateMeasurement rate="13" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1346"/>
               <rateMeasurement rate="2" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1350"/>
               <rateMeasurement rate="17" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1346"/>
               <rateMeasurement rate="4" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1348"/>
               <rateMeasurement rate="7" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="1348"/>
               <rateMeasurement rate="10" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="1350"/>
               <rateMeasurement rate="6" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1350"/>
               <rateMeasurement rate="10" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1346"/>
               <rateMeasurement rate="7" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1346"/>
               <rateMeasurement rate="6" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1348"/>
               <rateMeasurement rate="24" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Chest Pain"/>
               <arm id="1350"/>
               <rateMeasurement rate="1" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Chest Pain"/>
               <arm id="1346"/>
               <rateMeasurement rate="1" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1350"/>
               <rateMeasurement rate="10" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1346"/>
               <rateMeasurement rate="8" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1350"/>
               <rateMeasurement rate="14" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1348"/>
               <rateMeasurement rate="15" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1350"/>
               <rateMeasurement rate="24" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1348"/>
               <rateMeasurement rate="12" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1350"/>
               <rateMeasurement rate="4" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1350"/>
               <rateMeasurement rate="8" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1346"/>
               <rateMeasurement rate="27" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1350"/>
               <rateMeasurement rate="17" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1348"/>
               <rateMeasurement rate="21" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1350"/>
               <rateMeasurement rate="11" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1350"/>
               <rateMeasurement rate="8" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1346"/>
               <rateMeasurement rate="20" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1350"/>
               <rateMeasurement rate="57" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1350"/>
               <rateMeasurement rate="17" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1348"/>
               <rateMeasurement rate="16" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1346"/>
               <rateMeasurement rate="16" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="1346"/>
               <rateMeasurement rate="8" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1348"/>
               <rateMeasurement rate="27" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1346"/>
               <rateMeasurement rate="25" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1350"/>
               <rateMeasurement rate="8" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1350"/>
               <rateMeasurement rate="14" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1350"/>
               <rateMeasurement rate="13" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1346"/>
               <rateMeasurement rate="18" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1346"/>
               <rateMeasurement rate="4" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1346"/>
               <rateMeasurement rate="19" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1348"/>
               <rateMeasurement rate="8" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1348"/>
               <rateMeasurement rate="15" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1346"/>
               <rateMeasurement rate="6" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1348"/>
               <rateMeasurement rate="18" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1348"/>
               <rateMeasurement rate="8" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1346"/>
               <rateMeasurement rate="11" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1350"/>
               <rateMeasurement rate="18" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1348"/>
               <rateMeasurement rate="15" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1346"/>
               <rateMeasurement rate="17" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1348"/>
               <rateMeasurement rate="15" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1350"/>
               <rateMeasurement rate="2" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1348"/>
               <rateMeasurement rate="20" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1346"/>
               <rateMeasurement rate="12" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1348"/>
               <rateMeasurement rate="17" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1348"/>
               <rateMeasurement rate="9" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1346"/>
               <rateMeasurement rate="26" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1348"/>
               <rateMeasurement rate="7" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1348"/>
               <rateMeasurement rate="4" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1350"/>
               <rateMeasurement rate="4" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1346"/>
               <rateMeasurement rate="4" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1348"/>
               <rateMeasurement rate="15" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1346"/>
               <rateMeasurement rate="70" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1350"/>
               <rateMeasurement rate="8" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1348"/>
               <rateMeasurement rate="64" sampleSize="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1350"/>
               <rateMeasurement rate="23" sampleSize="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1348"/>
               <rateMeasurement rate="12" sampleSize="96"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Feighner et al, 1991">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Double-blind comparison of bupropion and fluoxetine in depressed outpatients</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>2</value>
               <notes/>
            </centers>
            <objective>
               <value>This study was undertaken to compare the efficacy and safety of bupropion and fluoxetine.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients had to (1) give written informed consent; (2) be at least 18 years old; (3) fulfill the DMS-III-R criteria for nonpsychotic major depressive episode (single or recurrent) which was not secondary to another preexisting psychiatric or medical condition; (4) have had the current depressive episode for at least 4 weeks but less than 2 years; (5) have a score of 20 or more on the 21-item HAM-D scale; and (6) be considered clinically appropriate for therapy with either bupropion or fluoxetine.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the study if they (1) had a predisposition to seizures; (2) had a current diagnosis or history of hepatic or renal dysfunction, thyroid disorder, anorexia nervosa or bulimia, or other unstable medical disorder; (3) were pregnant, lactating, or refused to employ an acceptable contraceptive method; (4) had a clinical history within the past year of alcohol or substance abuse; (5) had received psychoactive drugs within 1 week of the treatment phase (2 weeks for monoamine oxidase inhibitors or protriptyline and 4 weeks for investigational drugs); (6) had received previous treatment with bupropion or fluoxetine; (7) were currently receiving treatment with tryptophan, warfarin, digoxin, or thyroid preparations; (8) were unable to conduct a meaningful conversation or activity; or (9) were actively suicidal.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>1907963</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tinnitis">
               <adverseEvent name="Tinnitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Rash">
               <adverseEvent name="Rash"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flatulence">
               <adverseEvent name="Flatulence"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1496" size="62">
               <flexibleDose minDose="20.0" maxDose="80.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="1498" size="61">
               <flexibleDose minDose="225.0" maxDose="450.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Bupropion"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1498"/>
               <rateMeasurement rate="3" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1498"/>
               <rateMeasurement rate="10" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="1498"/>
               <rateMeasurement rate="7" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1496"/>
               <rateMeasurement rate="7" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tinnitis"/>
               <arm id="1498"/>
               <rateMeasurement rate="4" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1496"/>
               <rateMeasurement rate="18" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1496"/>
               <rateMeasurement rate="4" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1496"/>
               <rateMeasurement rate="7" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1496"/>
               <rateMeasurement rate="4" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1496"/>
               <rateMeasurement rate="6" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1498"/>
               <rateMeasurement rate="9" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1496"/>
               <rateMeasurement rate="10" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1498"/>
               <rateMeasurement rate="6" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="1496"/>
               <rateMeasurement rate="5" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1496"/>
               <rateMeasurement rate="2" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1498"/>
               <rateMeasurement rate="4" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1498"/>
               <rateMeasurement rate="4" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1498"/>
               <rateMeasurement rate="2" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flatulence"/>
               <arm id="1496"/>
               <rateMeasurement rate="3" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1498"/>
               <rateMeasurement rate="0" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1498"/>
               <rateMeasurement rate="37" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1496"/>
               <rateMeasurement rate="2" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1498"/>
               <rateMeasurement rate="10" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1496"/>
               <rateMeasurement rate="4" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1496"/>
               <rateMeasurement rate="35" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1496"/>
               <rateMeasurement rate="3" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1496"/>
               <rateMeasurement rate="5" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tinnitis"/>
               <arm id="1496"/>
               <rateMeasurement rate="1" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1498"/>
               <rateMeasurement rate="7" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1498"/>
               <rateMeasurement rate="1" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1498"/>
               <rateMeasurement rate="16" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1498"/>
               <rateMeasurement rate="6" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rash"/>
               <arm id="1496"/>
               <rateMeasurement rate="3" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flatulence"/>
               <arm id="1498"/>
               <rateMeasurement rate="2" sampleSize="61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1496"/>
               <rateMeasurement rate="3" sampleSize="62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rash"/>
               <arm id="1498"/>
               <rateMeasurement rate="0" sampleSize="61"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Franchini et al, 1997">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>1</value>
               <notes/>
            </centers>
            <objective>
               <value>We evaluated and compared the efficacy and safety of sertraline and fluvoxamine in a randomized, double-blind, parallel-group study during a follow-up of 24 months.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients consecutively admitted to the Research Center for Mood Disorders of the S. Raffaele Hospital in Milan for a recurrent, major depressive episode (DSM-IV criteria) (N = 273) were screened for the absence of other Axis I diagnoses, important physical illness, a history of low compliance to past treatments, mania or hypomania in first- and second-degree relatives, and prior long-term maintenance treatments and the presence of at least one depressive episode during the 18 months preceding the index episode. Patients with longer recurrence cycles were excluded to allow a meaningful comparison of the preventive efficacy of the maintenance treatments within our 24-month follow-up time limit. Seventy-seven patients met the selection criteria. At the time of recovery (4 months of remission confirmed by the absence of depressive symptoms according to DSM-IV criteria, absence of functional impairment,
and Hamilton Rating Scale for Depression [HAM-D] score &lt; 8), 64 of the patients (15 men and 49 women) gave their informed consent before entering the 2-year trial.</value>
               <notes/>
            </inclusion>
            <references>
               <pubMedId>9108811</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1578" size="32">
               <flexibleDose minDose="100.0" maxDose="200.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="1580" size="32">
               <flexibleDose minDose="200.0" maxDose="300.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluvoxamine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1580"/>
               <rateMeasurement rate="3" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1580"/>
               <rateMeasurement rate="3" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1578"/>
               <rateMeasurement rate="0" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1578"/>
               <rateMeasurement rate="0" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1580"/>
               <rateMeasurement rate="1" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1578"/>
               <rateMeasurement rate="2" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1578"/>
               <rateMeasurement rate="0" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1578"/>
               <rateMeasurement rate="4" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1580"/>
               <rateMeasurement rate="0" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1580"/>
               <rateMeasurement rate="0" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1580"/>
               <rateMeasurement rate="1" sampleSize="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1578"/>
               <rateMeasurement rate="0" sampleSize="32"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Gagiano 1993">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double blind comparison of paroxetine and fluoxetine in patients with major depression

British Journal of Clinical Research 1993; 4:145-152</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>Compare the efficacy of paroxetine and fluoxetine.</value>
               <notes/>
            </objective>
            <inclusion>
               <value>Male and female outpatients aged between 18 and 65 years. Patients were eligible if they had a diagnosis of a major depressive episode according to the DSM-III-R criteria and a score of 18 or more on the 21-item HAM-D scale. Patients were required to provide written informed consent to participation in this study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients excluded from the study included pregnant or lactating women and those with underlying renal, hepatic, neurological, gastrointestinal or severe cardiovascular disease, schizophrenia, organic brain syndrome and unstable diabetes. Recent treatment with MAOIs or neuroleptics, lithium therapy, ECT in the previous three months and alcohol or drug abuse were also reasons for exclusion. Patients considered to be at severe risk of suicide were ineligible for entry to the study.</value>
               <notes/>
            </exclusion>
            <references/>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1612" size="45">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="1614" size="45">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1612"/>
               <rateMeasurement rate="24" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1612"/>
               <rateMeasurement rate="5" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1612"/>
               <rateMeasurement rate="30" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1612"/>
               <rateMeasurement rate="8" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1614"/>
               <rateMeasurement rate="21" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1614"/>
               <rateMeasurement rate="9" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1612"/>
               <rateMeasurement rate="16" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1614"/>
               <rateMeasurement rate="6" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1612"/>
               <rateMeasurement rate="6" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1614"/>
               <rateMeasurement rate="15" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1614"/>
               <rateMeasurement rate="27" sampleSize="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1614"/>
               <rateMeasurement rate="10" sampleSize="45"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Goldstein et al, 2002">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>8</value>
               <notes/>
            </centers>
            <objective>
               <value>Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Participants were male and female outpatients, aged 18 to 65 years, who met criteria for nonpsychotic major depressive disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The diagnosis of major depressive disorder was confirmed by the Mini-International Neuropsychiatric Interview. In addition, patients were required to have a Clinical Global Impressions-Severity of Illness (CGI-S) rating of at least 4 (moderate) at visit 1 and a clinicianrated HAM-D-17 total score of at least 15 at visits 1 and 2.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had any primary DSM-IV Axis I diagnosis other than major depressive disorder or any anxiety disorder as a primary diagnosis within the past year, with the exception of specific phobias. Patients were also excluded if they had a history of substance abuse or dependence within the past year or had a positive urine drug screen at study entry. Patients could not have failed 2 or more adequate courses of antidepressant therapy during the current episode.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>11926722</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Rhinitis">
               <adverseEvent name="Rhinitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1645" size="33">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="1647" size="70">
               <flexibleDose minDose="40.0" maxDose="120.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Duloxetine"/>
               <notes/>
            </arm>
            <arm id="1649" size="70">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1645"/>
               <rateMeasurement rate="5" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1645"/>
               <rateMeasurement rate="12" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1647"/>
               <rateMeasurement rate="13" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1647"/>
               <rateMeasurement rate="12" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1645"/>
               <rateMeasurement rate="3" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1647"/>
               <rateMeasurement rate="14" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1647"/>
               <rateMeasurement rate="10" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1647"/>
               <rateMeasurement rate="34" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1645"/>
               <rateMeasurement rate="7" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1647"/>
               <rateMeasurement rate="24" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1649"/>
               <rateMeasurement rate="9" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1647"/>
               <rateMeasurement rate="8" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1649"/>
               <rateMeasurement rate="4" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1645"/>
               <rateMeasurement rate="10" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1649"/>
               <rateMeasurement rate="3" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1649"/>
               <rateMeasurement rate="3" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1649"/>
               <rateMeasurement rate="25" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1645"/>
               <rateMeasurement rate="2" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1649"/>
               <rateMeasurement rate="5" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1645"/>
               <rateMeasurement rate="15" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1647"/>
               <rateMeasurement rate="21" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1647"/>
               <rateMeasurement rate="11" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1649"/>
               <rateMeasurement rate="12" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1645"/>
               <rateMeasurement rate="7" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1649"/>
               <rateMeasurement rate="7" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1649"/>
               <rateMeasurement rate="7" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1647"/>
               <rateMeasurement rate="9" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1645"/>
               <rateMeasurement rate="5" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1645"/>
               <rateMeasurement rate="2" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1645"/>
               <rateMeasurement rate="3" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1647"/>
               <rateMeasurement rate="14" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1649"/>
               <rateMeasurement rate="12" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1649"/>
               <rateMeasurement rate="6" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1649"/>
               <rateMeasurement rate="5" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1647"/>
               <rateMeasurement rate="11" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1645"/>
               <rateMeasurement rate="6" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1649"/>
               <rateMeasurement rate="24" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1645"/>
               <rateMeasurement rate="11" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1647"/>
               <rateMeasurement rate="13" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1647"/>
               <rateMeasurement rate="7" sampleSize="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1645"/>
               <rateMeasurement rate="5" sampleSize="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1649"/>
               <rateMeasurement rate="22" sampleSize="70"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Hong et al, 2003">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed chinese patients</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>4</value>
               <notes/>
            </centers>
            <objective>
               <value>To compare the efficacy and tolerability of mirtazapine and fluoxetine treatment in a sample population consisting of Chinese patients suffering moderate-to-severe depression.</value>
               <notes/>
            </objective>
            <study_start>
               <value>1998-11-01</value>
               <notes/>
            </study_start>
            <study_end>
               <value>2000-06-30</value>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients were recruited from psychiatric outpatient departments. Inclusion criteria were (1) 18–75 years of age, (2) DSM-IV diagnosis of major depressive episode, (3) 17-item Hamilton Rating Scale for Depression (HAM-D)10 scores of 15 or more at baseline, (4) duration of current depressive episode between 1 week and 1 year, and (5) provision of informed consent.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Exclusion criteria were (1) pregnancy or lactation; (2) actual suicide risk; (3) history or current diagnosis of bipolar disorder, schizophrenia, psychotic symptoms, schizotypal or borderline personality disorder, or organic mental disorder; (4) current diagnosis (DSM-IV) of anxiety or eating disorder, postpartum depression, epilepsy, or history of seizures or alcohol or substance abuse during the preceding 6 months; (5) clinically relevant progressive disease including renal, cardiovascular, respiratory, or cerebrovascular problems or other serious physical ailments; and (6) clinically relevant abnormal findings during screening.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12927007</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Blurred Vision">
               <adverseEvent name="Blurred Vision"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Gain">
               <adverseEvent name="Weight Gain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1741" size="66">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="1743" size="66">
               <flexibleDose minDose="15.0" maxDose="45.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Mirtazapine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1741"/>
               <rateMeasurement rate="34" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blurred Vision"/>
               <arm id="1743"/>
               <rateMeasurement rate="3" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1743"/>
               <rateMeasurement rate="2" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1743"/>
               <rateMeasurement rate="2" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1741"/>
               <rateMeasurement rate="3" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1743"/>
               <rateMeasurement rate="7" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="1741"/>
               <rateMeasurement rate="1" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="1743"/>
               <rateMeasurement rate="38" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1741"/>
               <rateMeasurement rate="4" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1741"/>
               <rateMeasurement rate="20" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1741"/>
               <rateMeasurement rate="8" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1743"/>
               <rateMeasurement rate="5" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1743"/>
               <rateMeasurement rate="30" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="1741"/>
               <rateMeasurement rate="9" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1741"/>
               <rateMeasurement rate="4" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1743"/>
               <rateMeasurement rate="8" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blurred Vision"/>
               <arm id="1741"/>
               <rateMeasurement rate="6" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1743"/>
               <rateMeasurement rate="10" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1741"/>
               <rateMeasurement rate="6" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="1743"/>
               <rateMeasurement rate="0" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1743"/>
               <rateMeasurement rate="0" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1743"/>
               <rateMeasurement rate="13" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1741"/>
               <rateMeasurement rate="3" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1741"/>
               <rateMeasurement rate="3" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1741"/>
               <rateMeasurement rate="9" sampleSize="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="1743"/>
               <rateMeasurement rate="9" sampleSize="66"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Kavoussi et al, 1997">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>This randomized, double-blind, parallel-group trial was conducted to compare the efficacy and safety of bupropion SR and sertraline.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women at least 18 years of age who were diagnosed with major depressive disorder (DSM-IV) and currently experiencing a major depressive episode with duration ≥ 4 weeks but ≤ 24 months were eligible for the study if they provided written, informed consent. Patients were required to be in a stable relationship with normal sexual functioning.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Excluded were pregnant or lactating women, patients with a history or current diagnosis of bulimia and/or anorexia nervosa, patients with a known predisposition to seizures, and patients who were actively suicidal. Patients could not have been previously treated with either bupropion or sertraline and could not have received any psychoactive drug within 1 week of study drug treatment (2 weeks for monoamine oxidase inhibitors or protriptyline, and 4 weeks for fluoxetine). Patients were stratified by gender at randomization to ensure equivalence between treatment groups in their proportion of men and women.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>9448656</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1803" size="126">
               <flexibleDose minDose="50.0" maxDose="200.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="1805" size="122">
               <flexibleDose minDose="100.0" maxDose="300.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Bupropion"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1803"/>
               <rateMeasurement rate="40" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1805"/>
               <rateMeasurement rate="2" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1805"/>
               <rateMeasurement rate="2" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1803"/>
               <rateMeasurement rate="16" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1803"/>
               <rateMeasurement rate="13" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1803"/>
               <rateMeasurement rate="28" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1805"/>
               <rateMeasurement rate="4" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1805"/>
               <rateMeasurement rate="41" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1803"/>
               <rateMeasurement rate="37" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1805"/>
               <rateMeasurement rate="12" sampleSize="122"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1803"/>
               <rateMeasurement rate="43" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1805"/>
               <rateMeasurement rate="35" sampleSize="122"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Kiev and Feiger, 1997">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>2</value>
               <notes/>
            </centers>
            <objective>
               <value>Comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible patients aged 18 to 65 years who fulfilled the diagnostic criteria for a single or recurrent major depressive disorder, as defined by DSM-III-R, were recruited at two centers. The depressive disorder could be moderate or severe, without mood incongruent psychotic features. Women of childbearing potential were required to use appropriate birth control methods, and no pregnant or nursing patients were included in the study. A minimum total score of 20 on the 21-item Hamilton Rating Scale for Depression (HAM-D) and a minimum score of 2 on the "depressed mood" item of the HAM-D were required for study entry.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Those patients who were not fluent in written or oral English, had a history of medication noncompliance or substance abuse within the previous 6 months (other than nicotine), demonstrated a placebo response during screening (i.e., &gt;= 20% improvement on HAM-D total score), had been treated within 30 days with a drug with anticipated major organ toxicity, or had a severe risk of suicide or displayed autoaggressive behavior during the current depressive episode were not allowed to enter the study. Additional exclusion criteria included hypersensitivity to SSRIs, participation in previous fluvoxamine studies, other significant organic disease, clinically significant laboratory abnormalities, or other primary psychiatric diagnoses. Sufficient washout from other investigational drugs, prior psychotropic drugs, and electroconvulsive shock therapy was assured, and concomitant use of any psychotropic medications was prohibited. In addition, patients who would not be able to return for assessment due to transportation difficulties were excluded. While medications to treat gastrointestinal disturbances (antacids, laxatives), and headache (acetaminophen, aspirin, ibuprofen) and to provide nighttime sedation (chloral hydrate only) were permitted, all other medication use was prohibited unless approved by the study physician.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>9164424</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Impotence">
               <adverseEvent name="Impotence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Palpitation">
               <adverseEvent name="Palpitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dysmenorrhea">
               <adverseEvent name="Dysmenorrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dream Abnormality">
               <adverseEvent name="Dream Abnormality"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Depersonalization">
               <adverseEvent name="Depersonalization"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire">
               <adverseEvent name="Diminished Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flatulence">
               <adverseEvent name="Flatulence"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1837" size="30">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluvoxamine"/>
               <notes/>
            </arm>
            <arm id="1839" size="30">
               <flexibleDose minDose="20.0" maxDose="50.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1839"/>
               <rateMeasurement rate="8" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1839"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1839"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1839"/>
               <rateMeasurement rate="17" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Depersonalization"/>
               <arm id="1837"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="1837"/>
               <rateMeasurement rate="12" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flatulence"/>
               <arm id="1837"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1839"/>
               <rateMeasurement rate="3" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1839"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1839"/>
               <rateMeasurement rate="10" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="1839"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flatulence"/>
               <arm id="1839"/>
               <rateMeasurement rate="1" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1837"/>
               <continuousMeasurement mean="-1.9299999999999999" sampleSize="30" stdDev="1.22"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1839"/>
               <rateMeasurement rate="9" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1839"/>
               <rateMeasurement rate="6" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="1837"/>
               <rateMeasurement rate="7" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dysmenorrhea"/>
               <arm id="1839"/>
               <rateMeasurement rate="0" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="1839"/>
               <rateMeasurement rate="1" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1839"/>
               <rateMeasurement rate="5" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1837"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1837"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1839"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="1837"/>
               <rateMeasurement rate="2" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1837"/>
               <rateMeasurement rate="6" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1839"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1837"/>
               <rateMeasurement rate="12" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="1837"/>
               <rateMeasurement rate="7" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="1839"/>
               <continuousMeasurement mean="-1.52" sampleSize="30" stdDev="1.1799999999999999"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1837"/>
               <rateMeasurement rate="3" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="1839"/>
               <rateMeasurement rate="8" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1837"/>
               <rateMeasurement rate="2" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1837"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1837"/>
               <rateMeasurement rate="11" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Depersonalization"/>
               <arm id="1839"/>
               <rateMeasurement rate="2" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="1837"/>
               <rateMeasurement rate="3" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1837"/>
               <rateMeasurement rate="1" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1839"/>
               <rateMeasurement rate="9" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="1839"/>
               <rateMeasurement rate="3" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1837"/>
               <rateMeasurement rate="11" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="1837"/>
               <rateMeasurement rate="2" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="1839"/>
               <rateMeasurement rate="5" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1837"/>
               <rateMeasurement rate="9" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1839"/>
               <rateMeasurement rate="14" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dream Abnormality"/>
               <arm id="1837"/>
               <rateMeasurement rate="0" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1837"/>
               <rateMeasurement rate="2" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="1839"/>
               <rateMeasurement rate="5" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Palpitation"/>
               <arm id="1837"/>
               <rateMeasurement rate="4" sampleSize="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dysmenorrhea"/>
               <arm id="1837"/>
               <rateMeasurement rate="3" sampleSize="30"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Lepola et al, 2003">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>69</value>
               <notes/>
            </centers>
            <objective>
               <value>Escitalopram was compared to placebo in moderately to severely depressed patients in primary care with citalopram as the active reference.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients of either sex were eligible for the study if they fulfilled the DSM-IV criteria for MDD, had a baseline Montgomery – Asberg Depression Rating Scale (MADRS) total score &gt;= 22 and &lt;= 40, and were aged between 18 and 65 years. Investigators also screened patients on the basis of physical examination, medical history, electrocardiogram (ECG) and clinical laboratory tests.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were ineligible for the study if they met any of the following criteria: suffering from mania or any bipolar disorder, schizophrenia or any psychotic disorder, obsessive–compulsive disorder, eating disorders, mental retardation, any pervasive developmental disorder or cognitive disorder (according to DSM-IV criteria), MADRS score &gt;= 5 on item 10 (suicidal thoughts), treatment with antipsychotics, antidepressants, hypnotics, anxiolytics (except benzodiazepines for insomnia), barbiturates, chloral hydrate, or other 5-hydroxytryptamine receptor agonists, electroconvulsive treatment, treatment with behaviour therapy or psychotherapy.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12817155</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Impotence">
               <adverseEvent name="Impotence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Rhinitis">
               <adverseEvent name="Rhinitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="1943" size="160">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Citalopram"/>
               <notes/>
            </arm>
            <arm id="1945" size="155">
               <flexibleDose minDose="10.0" maxDose="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Escitalopram"/>
               <notes/>
            </arm>
            <arm id="1947" size="154">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1945"/>
               <rateMeasurement rate="5" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1945"/>
               <rateMeasurement rate="0" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1945"/>
               <rateMeasurement rate="10" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1945"/>
               <rateMeasurement rate="9" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1947"/>
               <rateMeasurement rate="2" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1945"/>
               <rateMeasurement rate="2" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1943"/>
               <rateMeasurement rate="2" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1947"/>
               <rateMeasurement rate="14" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1943"/>
               <rateMeasurement rate="5" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1943"/>
               <rateMeasurement rate="12" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1943"/>
               <rateMeasurement rate="7" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1943"/>
               <rateMeasurement rate="10" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="1947"/>
               <rateMeasurement rate="74" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1945"/>
               <rateMeasurement rate="14" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1947"/>
               <rateMeasurement rate="15" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1947"/>
               <rateMeasurement rate="3" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="1945"/>
               <rateMeasurement rate="9" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1943"/>
               <rateMeasurement rate="8" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1947"/>
               <rateMeasurement rate="2" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="1947"/>
               <rateMeasurement rate="5" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1945"/>
               <rateMeasurement rate="3" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="1943"/>
               <rateMeasurement rate="27" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="1947"/>
               <rateMeasurement rate="3" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="1945"/>
               <rateMeasurement rate="2" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="1947"/>
               <rateMeasurement rate="0" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="1945"/>
               <rateMeasurement rate="99" sampleSize="155"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="1943"/>
               <rateMeasurement rate="7" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Rhinitis"/>
               <arm id="1947"/>
               <rateMeasurement rate="9" sampleSize="154"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="1943"/>
               <rateMeasurement rate="84" sampleSize="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="1943"/>
               <rateMeasurement rate="7" sampleSize="160"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="McPartlin et al, 1998">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice.

Primary Care Psychiatry 1998; 4: 127-132</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>43</value>
               <notes/>
            </centers>
            <objective>
               <value>To evaluate the efficacy and safety of venlafaxine XR and paroxetine for the treatment of depression in general practice in the UK.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male or female outpatients at least 18 years of age were eligible if they satisfied DSM-IV criteria for major depression, had symptoms of depression for at least 14 days, and had a minimum baseline score of 19 on the MADRS scale.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients hypersensitive to or previously treated with the study drugs were excluded. Female patients of childbearing potential were excluded unless they had a negative urine beta-human chorionic gonadotropin (beta-hCG) test at screening and maintained an acceptable form of contraception throughout the trial. Patients with a history of clinically significant abnormalities on a screening physical examination, electrocardiogram (ECG) or laboratory tests were excluded. In addition, patients were excluded if they had acute suicidal tendencies, seizure disorder, presence of an organic mental disorder, bipolar disorder or a history of any psychotic disorder not associated with depression. The use of any investigational drug, antipsychotic drug, electroconvulsive therapy (ECT), sumatriptan, monoamine oxidase inhibitor or other antidepressant drug, anxiolytic or sedative-hypnotic drug (except temazepam or zopiclone) or any other psychotropic drug or substance within 30 days of baseline were reasons for exclusion. A history of drug or alcohol abuse within two years of the start of the study were also reasons for exclusion.</value>
               <notes/>
            </exclusion>
            <references/>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2015" size="183">
               <fixedDose quantity="75.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="2017" size="178">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2017"/>
               <rateMeasurement rate="8" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2017"/>
               <rateMeasurement rate="8" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2017"/>
               <rateMeasurement rate="11" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2017"/>
               <rateMeasurement rate="128" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2017"/>
               <rateMeasurement rate="10" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2015"/>
               <rateMeasurement rate="18" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2015"/>
               <rateMeasurement rate="7" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2017"/>
               <rateMeasurement rate="21" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2017"/>
               <rateMeasurement rate="12" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2015"/>
               <rateMeasurement rate="46" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2015"/>
               <rateMeasurement rate="30" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2017"/>
               <rateMeasurement rate="52" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2015"/>
               <rateMeasurement rate="8" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="2015"/>
               <continuousMeasurement mean="-2.2999999999999998" sampleSize="183" stdDev="1.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2017"/>
               <rateMeasurement rate="17" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2015"/>
               <rateMeasurement rate="14" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2015"/>
               <rateMeasurement rate="4" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2015"/>
               <rateMeasurement rate="16" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2017"/>
               <rateMeasurement rate="9" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2017"/>
               <rateMeasurement rate="12" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2015"/>
               <rateMeasurement rate="47" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2017"/>
               <rateMeasurement rate="44" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2015"/>
               <rateMeasurement rate="10" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2015"/>
               <rateMeasurement rate="10" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2017"/>
               <rateMeasurement rate="6" sampleSize="178"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2015"/>
               <rateMeasurement rate="137" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2015"/>
               <rateMeasurement rate="10" sampleSize="183"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="2017"/>
               <continuousMeasurement mean="-2.2999999999999998" sampleSize="178" stdDev="1.3999999999999999"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Mehtonen et al, 2000">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>This 8-week, double-blind, randomized trial compared the efficacy and tolerability of venlafaxine and sertraline in patients with major depression.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients aged 18 to 65 years were eligible if they met DSM-IV criteria for major depressive disorder, had a minimum baseline score of 18 on the 21-item Hamilton Rating Scale for Depression (HAM-D) with a decrease of not more than 20% between screening and baseline, and had symptoms of depression for at least 14 days before study entry. Women of childbearing potential were required to have a negative urine pregnancy test and to use a medically acceptable method of contraception during the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients with a known sensitivity to venlafaxine or sertraline or with a history of any clinically significant cardiac, hepatic, or renal disease or clinically significant abnormalities at a screening examination were excluded. Also excluded were patients with acute suicidal tendencies, a history of a seizure disorder, history or presence of any psychotic disorder not associated with depression, or history of drug or alcohol dependence within the past 2 years. Patients were precluded from participation if they were using any investigational drug, antipsychotic drug, neuroleptic drug, or electroconvulsive therapy within 30 days; fluoxetine within 21 days; a monoamine oxidase inhibitor or other antidepressant within 14 days; or a benzodiazepine (except oxazepam or temazepam) or other anxiolytic or sedative hypnotic within 7 days of baseline. Use of any nonpsychotropic drug with psychotropic effects was precluded unless the dosage had been stable for at least 1 month prior to treatment.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10732656</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction">
               <adverseEvent name="Sexual Dysfunction"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2080" size="75">
               <flexibleDose minDose="75.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="2082" size="72">
               <flexibleDose minDose="50.0" maxDose="100.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2082"/>
               <rateMeasurement rate="8" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2082"/>
               <rateMeasurement rate="21" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2080"/>
               <rateMeasurement rate="5" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2080"/>
               <rateMeasurement rate="10" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2080"/>
               <rateMeasurement rate="14" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2080"/>
               <rateMeasurement rate="8" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2082"/>
               <rateMeasurement rate="5" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2080"/>
               <rateMeasurement rate="21" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2082"/>
               <rateMeasurement rate="21" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2082"/>
               <rateMeasurement rate="12" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2082"/>
               <rateMeasurement rate="10" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2082"/>
               <rateMeasurement rate="8" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2080"/>
               <rateMeasurement rate="16" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2082"/>
               <rateMeasurement rate="41" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2080"/>
               <rateMeasurement rate="9" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2080"/>
               <rateMeasurement rate="6" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction"/>
               <arm id="2082"/>
               <rateMeasurement rate="4" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2080"/>
               <rateMeasurement rate="27" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2080"/>
               <rateMeasurement rate="49" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sexual Dysfunction"/>
               <arm id="2080"/>
               <rateMeasurement rate="6" sampleSize="75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2082"/>
               <rateMeasurement rate="8" sampleSize="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2082"/>
               <rateMeasurement rate="7" sampleSize="72"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Montgomery et al, 2004">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>44</value>
               <notes/>
            </centers>
            <objective>
               <value>This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible patients were patients in primary care, 18–85 years of age, with a DSM-IV diagnosis of MDD and a minimum score of 18 on the MADRS scale.
</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they met any of the following criteria: history of mania or any bipolar disorder, schizophrenia or any psychotic disorder, or were currently suffering from obsessive-compulsive disorder, eating disorders, mental retardation, any pervasive development disorder, or cognitive disorder (DSM-IV criteria); MADRS score 65 on item 10 (suicidal thoughts); alcohol or drug abuse problems within the previous 12 months; or had had treatment with antipsychotics, antidepressants, psychotropics (except zolpidem or stable low doses of benzodiazepines for insomnia), serotonin receptor agonists, lithium, carbamazepine, valproate, or valpromide; electroconvulsive treatment; treatment with behaviour therapy or psychotherapy; or if they were pregnant or breast feeding. Medications thought likely to interfere with the study were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15179022</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Impotence">
               <adverseEvent name="Impotence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Loss">
               <adverseEvent name="Weight Loss"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Back Pain">
               <adverseEvent name="Back Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2134" size="145">
               <flexibleDose minDose="75.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="2136" size="148">
               <flexibleDose minDose="10.0" maxDose="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Escitalopram"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2134"/>
               <rateMeasurement rate="14" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2136"/>
               <rateMeasurement rate="5" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2136"/>
               <rateMeasurement rate="21" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2136"/>
               <rateMeasurement rate="10" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2136"/>
               <rateMeasurement rate="6" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2134"/>
               <rateMeasurement rate="38" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2136"/>
               <rateMeasurement rate="25" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2134"/>
               <rateMeasurement rate="18" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2134"/>
               <rateMeasurement rate="113" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2136"/>
               <rateMeasurement rate="113" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2136"/>
               <rateMeasurement rate="9" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="2134"/>
               <rateMeasurement rate="9" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2136"/>
               <rateMeasurement rate="11" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2136"/>
               <rateMeasurement rate="3" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="2136"/>
               <rateMeasurement rate="2" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2134"/>
               <rateMeasurement rate="9" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="2134"/>
               <rateMeasurement rate="10" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2134"/>
               <rateMeasurement rate="9" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2136"/>
               <rateMeasurement rate="19" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2134"/>
               <rateMeasurement rate="9" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="2136"/>
               <rateMeasurement rate="8" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="2136"/>
               <rateMeasurement rate="5" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back Pain"/>
               <arm id="2136"/>
               <rateMeasurement rate="9" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2134"/>
               <rateMeasurement rate="9" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2134"/>
               <rateMeasurement rate="9" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back Pain"/>
               <arm id="2134"/>
               <rateMeasurement rate="10" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2136"/>
               <rateMeasurement rate="9" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="2134"/>
               <rateMeasurement rate="1" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2134"/>
               <rateMeasurement rate="4" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2134"/>
               <rateMeasurement rate="19" sampleSize="145"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2136"/>
               <rateMeasurement rate="7" sampleSize="148"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2134"/>
               <rateMeasurement rate="13" sampleSize="145"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Nemeroff et al, 1995">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients.

Depression 1995; 3:163-169</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>5</value>
               <notes/>
            </centers>
            <objective>
               <value>Comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients aged 18 to 65 years who fulfilled the DSM-III-R criteria for MDD, were recruited for study participation. Women of childbearing potential were required to use appropriate birth control methods and no pregnant or nursing patients were included in the study. A minimum total score of 20, on the 21-item HAM-D scale, a minimum score of 2 on the "depressed mood" item on the HAM-D, a minimum score of 8 on the Raskin Depression Scale and a Covi Anxiety Scale score less than the Raskin score were required for study entry.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded who did not have written and oral fluency in the English language, had a history of noncompliance, who demonstrated a response during the placebo washout period of 1-2 weeks (i.e., &gt;= 20% improvement on HAM-D total score), had been treated within 30 days with a drug having possible toxic effects on major organs, or had a severe risk of suicide (&gt;= 21 on the Modified Scale for Suicidal Indications [MSSI]). Additional exclusions included patients whoe were intolerant to SSRI side effects, had participated in previous fluvoxamine studies, or had other significant organic disieas or other primary psychiatric diagnoses. At least 2 weeks of washout from prior psychotropic drugs and electroconvulsive shock therapy was required, and concomitant use of any psychotropic medications, other than chloral hydrate for nighttime sedation, was prohibited. While medications to treat gastrointestinal disturbances and headache were permitted, all other medication use was prohibited unless approved by the study physician.</value>
               <notes/>
            </exclusion>
            <references/>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-CGI Severity Change">
               <endpoint name="CGI Severity Change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Impotence">
               <adverseEvent name="Impotence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation">
               <adverseEvent name="Abnormal Ejaculation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Pharyngitis">
               <adverseEvent name="Pharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire">
               <adverseEvent name="Diminished Sexual Desire"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Infection">
               <adverseEvent name="Infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2208" size="46">
               <flexibleDose minDose="50.0" maxDose="200.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="2210" size="49">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluvoxamine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2208"/>
               <rateMeasurement rate="6" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2210"/>
               <rateMeasurement rate="3" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2208"/>
               <rateMeasurement rate="3" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2210"/>
               <rateMeasurement rate="13" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2210"/>
               <rateMeasurement rate="4" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngitis"/>
               <arm id="2210"/>
               <rateMeasurement rate="7" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="2210"/>
               <continuousMeasurement mean="-1.35" sampleSize="49" stdDev="1.23"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2210"/>
               <rateMeasurement rate="15" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2210"/>
               <rateMeasurement rate="3" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2208"/>
               <rateMeasurement rate="5" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2210"/>
               <rateMeasurement rate="4" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2210"/>
               <rateMeasurement rate="9" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2208"/>
               <rateMeasurement rate="16" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2210"/>
               <rateMeasurement rate="5" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2208"/>
               <rateMeasurement rate="11" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2210"/>
               <rateMeasurement rate="3" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2208"/>
               <rateMeasurement rate="6" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2210"/>
               <rateMeasurement rate="7" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2210"/>
               <rateMeasurement rate="12" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2210"/>
               <rateMeasurement rate="6" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2208"/>
               <rateMeasurement rate="10" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2208"/>
               <rateMeasurement rate="8" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngitis"/>
               <arm id="2208"/>
               <rateMeasurement rate="1" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="2210"/>
               <rateMeasurement rate="2" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2210"/>
               <rateMeasurement rate="9" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2210"/>
               <rateMeasurement rate="7" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2210"/>
               <rateMeasurement rate="5" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2208"/>
               <rateMeasurement rate="15" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2208"/>
               <rateMeasurement rate="10" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="2208"/>
               <rateMeasurement rate="9" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2208"/>
               <rateMeasurement rate="7" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2208"/>
               <rateMeasurement rate="6" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Impotence"/>
               <arm id="2208"/>
               <rateMeasurement rate="0" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2208"/>
               <rateMeasurement rate="1" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="2210"/>
               <rateMeasurement rate="1" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diminished Sexual Desire"/>
               <arm id="2210"/>
               <rateMeasurement rate="3" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abnormal Ejaculation"/>
               <arm id="2208"/>
               <rateMeasurement rate="4" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2210"/>
               <rateMeasurement rate="13" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2208"/>
               <rateMeasurement rate="7" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2208"/>
               <rateMeasurement rate="4" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2208"/>
               <rateMeasurement rate="5" sampleSize="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-CGI Severity Change"/>
               <arm id="2208"/>
               <continuousMeasurement mean="-1.52" sampleSize="46" stdDev="0.95999999999999996"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Newhouse et al, 2000">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>This multicenter study was designed to examine the efficacy and safety of sertraline and fluoxetine in depressed elderly outpatients. A secondary objective was to examine the effects of SSRI treatment on quality of life and cognitive function.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Outpatients 60 years of age or older who met the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) criteria for major depressive disorder (single episode or recurrent, without psychotic features) and had a total score of 18 or more on the 24-item Hamilton Rating Scale for Depression (HAM-D) at the end of the washout were eligible for this study. Written informed consent was obtained from all patients prior to study entry.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Complete psychiatric histories were taken, and patients were excluded if they met DSM-III-R diagnostic criteria for any other psychiatric disorders. In addition, patients were required to score at least 24 on the Mini-Mental State Examination (MMSE)26 to exclude significant cognitive impairment. Subjects were also excluded if they had any medical contraindications to antidepressant therapy; significant hematologic, endocrine, or cardiovascular disease; and conditions that might impair study drug absorption, metabolism, or excretion. Additional exclusions included failure to respond to electroconvulsive therapy in a prior depressive episode or to adequate trials (6 weeks) of 2 or more antidepressants in daily doses equivalent to 150 mg of amitriptyline administered for 3 weeks. Patients were informed that all other psychotropic medications (except temazepam or chloral hydrate used sparingly for sleep) were to be discontinued prior to entry into the study. This criterion was verified by urinalysis performed at the initial visit.

Patients had to be free of any clinically significant medical problems. Complete medical histories were taken, and a thorough physical examination was performed prior to study entry. A 12-lead electrocardiogram was recorded at day 1 of washout (and at the end of weeks 4 and 12 or when a patient discontinued the study). Normal baseline laboratory values were required, but patients with clinically insignificant abnormalities were eligible.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10982198</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2301" size="117">
               <flexibleDose minDose="50.0" maxDose="100.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="2303" size="119">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2301"/>
               <rateMeasurement rate="17" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2303"/>
               <rateMeasurement rate="14" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2301"/>
               <rateMeasurement rate="39" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2303"/>
               <rateMeasurement rate="22" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2301"/>
               <rateMeasurement rate="18" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2301"/>
               <rateMeasurement rate="11" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2303"/>
               <rateMeasurement rate="84" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2303"/>
               <rateMeasurement rate="12" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2303"/>
               <rateMeasurement rate="15" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2303"/>
               <rateMeasurement rate="17" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2301"/>
               <rateMeasurement rate="26" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2303"/>
               <rateMeasurement rate="37" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2301"/>
               <rateMeasurement rate="17" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2301"/>
               <rateMeasurement rate="85" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2303"/>
               <rateMeasurement rate="25" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2303"/>
               <rateMeasurement rate="19" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2301"/>
               <rateMeasurement rate="20" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2301"/>
               <rateMeasurement rate="16" sampleSize="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2303"/>
               <rateMeasurement rate="9" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2301"/>
               <rateMeasurement rate="9" sampleSize="117"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Patris et al, 1996">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>46</value>
               <notes/>
            </centers>
            <objective>
               <value>Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>All patients recruited for the study weer seen and treated by general practitioners. Patients of either sex, aged between 21 and 73 years, who had given signed informed consent to participate and who fulfilled the DSM-III-R criteria for unipolar major depression of a severity corresponding to a MADRS total score of at least 22 entered the trial.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Exclusion criteria were: dysthymia or cyclothymia (DSM-III-R), decrease in MADRS total score &gt;20% during the 7 days run-in period, pregnancy, lactation, alcohol or drug abuse within the past year, treatment with MAO-inhibitors within the past 2 weeks, severe somatic disease, organic brain syndrome, schizophrenia, epilepsy or other neurological diseases, suicide risk, known hypersensitivity to citalopram or fluoxetine or other drugs, failure to use an accpetable contraceptive method.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>8803650</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Loss">
               <adverseEvent name="Weight Loss"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Back Pain">
               <adverseEvent name="Back Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Bronchitis">
               <adverseEvent name="Bronchitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Abdominal Pain">
               <adverseEvent name="Abdominal Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2351" size="173">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Citalopram"/>
               <notes/>
            </arm>
            <arm id="2353" size="184">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2353"/>
               <rateMeasurement rate="21" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal Pain"/>
               <arm id="2353"/>
               <rateMeasurement rate="5" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2351"/>
               <rateMeasurement rate="2" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2351"/>
               <rateMeasurement rate="6" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2351"/>
               <rateMeasurement rate="8" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2353"/>
               <rateMeasurement rate="7" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm id="2353"/>
               <rateMeasurement rate="7" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2351"/>
               <rateMeasurement rate="2" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2351"/>
               <rateMeasurement rate="8" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="2353"/>
               <rateMeasurement rate="15" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2351"/>
               <rateMeasurement rate="0" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2353"/>
               <rateMeasurement rate="6" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2351"/>
               <rateMeasurement rate="17" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2351"/>
               <rateMeasurement rate="24" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2353"/>
               <rateMeasurement rate="93" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2353"/>
               <rateMeasurement rate="9" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2353"/>
               <rateMeasurement rate="10" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back Pain"/>
               <arm id="2351"/>
               <rateMeasurement rate="5" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2351"/>
               <rateMeasurement rate="94" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2353"/>
               <rateMeasurement rate="14" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2353"/>
               <rateMeasurement rate="2" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2353"/>
               <rateMeasurement rate="1" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Loss"/>
               <arm id="2351"/>
               <rateMeasurement rate="6" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2351"/>
               <rateMeasurement rate="5" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal Pain"/>
               <arm id="2351"/>
               <rateMeasurement rate="4" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2353"/>
               <rateMeasurement rate="6" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2351"/>
               <rateMeasurement rate="6" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm id="2351"/>
               <rateMeasurement rate="5" sampleSize="173"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back Pain"/>
               <arm id="2353"/>
               <rateMeasurement rate="0" sampleSize="184"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2353"/>
               <rateMeasurement rate="5" sampleSize="184"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Rapaport et al, 1996">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A comparison of fluvoxamine and fluoxetine in the treatment of major depression.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>This is the first study in the United States to compare the efficacy and tolerability of fluvoxamine (100-150 mg/day) and fluoxetine (20-80 mg/day).</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The subjects in this trial were solicited volunteers who answered advertisements in the newspaper and on the radio for free outpatient research treatment of major depression. All patients provided informed, written consent to participate in the study and were between the ages of 18 and 65 years. Women of childbearing potential were required to use appropriate birth control methods, and pregnant or nursing patients were excluded from the study. Patients met DSM-III-R criteria for a current major depressive episode and had a minimum total score of 20 on the 21-item Hamilton Rating Scale for Depression (HAM-D) with a minimum score of 2 on the depressed mood item at screening and baseline visits. Patients were recruited from six sites.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>The subjects underwent complete psychiatric and medical histories, physical examinations, and laboratory tests. Hematology and serum chemistry tests were performed at screening, baseline, and week 7. Patients with unstable medical conditions, other axis I diagnoses, acute suicidality (a score greater or equal to 21 on the Modified Scale for Suicidal Ideation), a history of substance dependence within 6 months of the study, or a history of a seizure disorder were excluded from the study. Patients who responded to placebo (greater or equal to 20% improvement on the HAM-D) during the screening phase were not randomized to double-blind treatment. All patients were medication-free for at least 2 weeks before the study and were excluded if they had been treated with either fluvoxamine or fluoxetine before enrollment. Only chloral hydrate (up to a maximum of 1,000 mg/day) was allowed as adjuvant medication for insomnia during the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>8889909</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2421" size="51">
               <flexibleDose minDose="100.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluvoxamine"/>
               <notes/>
            </arm>
            <arm id="2423" size="49">
               <flexibleDose minDose="20.0" maxDose="80.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2423"/>
               <rateMeasurement rate="14" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2423"/>
               <rateMeasurement rate="21" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2421"/>
               <rateMeasurement rate="11" sampleSize="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2421"/>
               <rateMeasurement rate="9" sampleSize="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2421"/>
               <rateMeasurement rate="6" sampleSize="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2423"/>
               <rateMeasurement rate="12" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2421"/>
               <rateMeasurement rate="4" sampleSize="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="2423"/>
               <rateMeasurement rate="23" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2421"/>
               <rateMeasurement rate="18" sampleSize="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2423"/>
               <rateMeasurement rate="4" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2423"/>
               <rateMeasurement rate="26" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="2421"/>
               <rateMeasurement rate="16" sampleSize="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2423"/>
               <rateMeasurement rate="14" sampleSize="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2421"/>
               <rateMeasurement rate="26" sampleSize="51"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Rudolph and Feiger, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>We compared the efficacy and tolerability of venlafaxine XR with that of fluoxetine in a multicenter, randomized, double-blind, placebo-controlled study in depressed outpatients.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The study population consisted of outpatients age 18 years and older who met Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for major depressive disorder. The diagnosis of major depressive disorder was based on a clinical interview of the patient and subsequent completion by the investigator of a worksheet containing the DSM IV criteria. In addition, patients had to have symptoms of depression for at least one month before study entry, and they had to have minimum prestudy and baseline (after washout) scores of 20 on the 21-item Hamilton Rating Scale for Depression (HAM-D-21).</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from study participation if they had recent (within six months) treatment with or a known hypersensitivity to either of the active study drugs, certain specified medical conditions, bipolar mood disorder, a psychotic disorder not associated with depression, or a history of drug or alcohol dependence within a year of study entry. Acutely suicidal patients and pregnant or lactating women were also excluded. Patients whose HAM-D-21 score decreased by more than 20% from the prestudy evaluation to the baseline evaluation were excluded from randomization. Each prospective study patient gave written informed consent.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10701474</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Infection">
               <adverseEvent name="Infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2459" size="100">
               <flexibleDose minDose="75.0" maxDose="225.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="2461" size="103">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="2463" size="98">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2463"/>
               <rateMeasurement rate="21" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2463"/>
               <rateMeasurement rate="4" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2461"/>
               <rateMeasurement rate="8" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2459"/>
               <rateMeasurement rate="26" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2463"/>
               <rateMeasurement rate="14" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2459"/>
               <rateMeasurement rate="19" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2461"/>
               <rateMeasurement rate="10" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2459"/>
               <rateMeasurement rate="7" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2459"/>
               <rateMeasurement rate="10" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2461"/>
               <rateMeasurement rate="28" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2463"/>
               <rateMeasurement rate="38" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2463"/>
               <rateMeasurement rate="6" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2463"/>
               <rateMeasurement rate="1" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2461"/>
               <rateMeasurement rate="19" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2459"/>
               <rateMeasurement rate="9" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2461"/>
               <rateMeasurement rate="11" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2459"/>
               <rateMeasurement rate="26" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2459"/>
               <rateMeasurement rate="12" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2459"/>
               <rateMeasurement rate="14" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2463"/>
               <rateMeasurement rate="4" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2463"/>
               <rateMeasurement rate="2" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2463"/>
               <rateMeasurement rate="9" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2461"/>
               <rateMeasurement rate="6" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2459"/>
               <rateMeasurement rate="10" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2459"/>
               <rateMeasurement rate="58" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2461"/>
               <rateMeasurement rate="10" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2459"/>
               <rateMeasurement rate="57" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2461"/>
               <rateMeasurement rate="52" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2463"/>
               <rateMeasurement rate="3" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2461"/>
               <rateMeasurement rate="10" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2461"/>
               <rateMeasurement rate="11" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2459"/>
               <rateMeasurement rate="13" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2461"/>
               <rateMeasurement rate="5" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2461"/>
               <rateMeasurement rate="53" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2463"/>
               <rateMeasurement rate="6" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2461"/>
               <rateMeasurement rate="20" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2463"/>
               <rateMeasurement rate="5" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2459"/>
               <rateMeasurement rate="9" sampleSize="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2463"/>
               <rateMeasurement rate="7" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2463"/>
               <rateMeasurement rate="41" sampleSize="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2461"/>
               <rateMeasurement rate="12" sampleSize="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2459"/>
               <rateMeasurement rate="8" sampleSize="100"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Schatzberg et al, 2002">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Double-blind randomized comparison of mirtazapine and paroxetine in elderly depressed patients</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>18</value>
               <notes/>
            </centers>
            <objective>
               <value>Authors studied the efficacy and tolerability of mirtazapine and paroxetine in elderly patients with major depression during an acute phase (8 weeks) and an extension phase (16 weeks).</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients at least 65 years of age were eligible. Participants in the study were outpatients recruited through advertising, private practices, and routine intake at clinics and other healthcare facilities. At the screening visit, patients were required to satisfy DSM-IV criteria for a single or recurrent major depressive episode, have a Mini-Mental State Exam (MMSE) score above the 25th percentile for age and educational level,17 and score at least 18 on the 17-item Hamilton Rating Scale for Depression (Ham-D–17).</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if their Ham-D score decreased by 20% or more between the screening and baseline visits. Patients with concomitant medical illnesses (e.g., diabetes, high blood pressure, hypothyroidism, or chronic respiratory or other medical condition) were eligible for the study if their condition was stable for at least 3 months and they had been receiving standard therapy for the condition for at least 1 month.

Patients were excluded for any untreated or unstable clinically significant medical condition or any clinically significant laboratory or physical examination abnormality or thyroid function abnormality. A history of seizures, recent drug or alcohol abuse, or any principal psychiatric condition other than major depression were reasons for exclusion, as were the presence of psychotic features or suicide attempt in the current depressive episode. Patients were excluded if they had received a monoamine oxidase inhibitor within 14 days, other psychotropic drugs or herbal treatments for depression within 7 days, paroxetine or mirtazapine for the current depressive episode, or electroconvulsive therapy within the previous 6 months. Patients also were excluded if they required concomitant therapy with drugs approved for the treatment of memory deficits. Patients who did not tolerate or respond to mirtazapine or paroxetine during a previous depressive episode were ineligible. Also, patients who had failed more than one adequate trial of antidepressant treatment for the current depressive episode were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12213688</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Weight Gain">
               <adverseEvent name="Weight Gain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flatulence">
               <adverseEvent name="Flatulence"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2555" size="120">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="2557" size="126">
               <flexibleDose minDose="15.0" maxDose="45.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Mirtazapine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="2555"/>
               <rateMeasurement rate="15" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2555"/>
               <rateMeasurement rate="14" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="2555"/>
               <rateMeasurement rate="0" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2557"/>
               <rateMeasurement rate="8" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2555"/>
               <rateMeasurement rate="17" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2557"/>
               <rateMeasurement rate="39" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2557"/>
               <rateMeasurement rate="8" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2555"/>
               <rateMeasurement rate="24" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flatulence"/>
               <arm id="2557"/>
               <rateMeasurement rate="4" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2557"/>
               <rateMeasurement rate="20" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2555"/>
               <rateMeasurement rate="69" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2557"/>
               <rateMeasurement rate="29" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2555"/>
               <rateMeasurement rate="14" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2557"/>
               <rateMeasurement rate="5" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2557"/>
               <rateMeasurement rate="34" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2557"/>
               <rateMeasurement rate="19" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2555"/>
               <rateMeasurement rate="37" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2557"/>
               <rateMeasurement rate="15" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2557"/>
               <rateMeasurement rate="20" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flatulence"/>
               <arm id="2555"/>
               <rateMeasurement rate="15" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2555"/>
               <rateMeasurement rate="31" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2555"/>
               <rateMeasurement rate="14" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2557"/>
               <rateMeasurement rate="15" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2555"/>
               <rateMeasurement rate="18" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2555"/>
               <rateMeasurement rate="13" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2557"/>
               <rateMeasurement rate="81" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="2557"/>
               <rateMeasurement rate="22" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2555"/>
               <rateMeasurement rate="39" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weight Gain"/>
               <arm id="2557"/>
               <rateMeasurement rate="14" sampleSize="126"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2555"/>
               <rateMeasurement rate="22" sampleSize="120"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Schone and Ludwig, 1993">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>6</value>
               <notes/>
            </centers>
            <objective>
               <value>The study compared the efficacy and tolerability of paroxetine and fluoxetine in 106 depressed geriatric outpatients (age, &gt; or = 65 years). </value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The study population comprised 92 women and 14 men, aged 65 to 85 years; the mean age was 74 years. All patients fullfilled DSM-III-R criteria for a current episode of major depression and were required to have a score of 18 or more on the first 17 items of the 21-item HAM-D scale. All patients gave written informed consent to study participation.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the study if they had severe physical illness, senile dementia, schizophrenia, or organic brain syndrome, or if they were known abusers of alcohol. Other exclusion criteria included electroconvulsive therapy during the 3 months before study entry, the use of MAOIs during the previous 2 weeks, the use of depot neuroleptics during the previous 4 weeks, and the use of oral neuroleptics during the previous 2 weeks. The use of concomitant psychotropic medications was prohibited during the study, with the exception of temazepam (15 to 30 mg) as needed for sleep disturbance.

Any patient whose HAM-D total score decreased by 20% or more during a placebo washout period was excluded from the study. Although the placebo washout period for most patients was 7 days, the protocol allowed a 3- to 7-day range.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>8106654</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-MADRS Responders">
               <endpoint name="MADRS Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vertigo">
               <adverseEvent name="Vertigo"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2625" size="54">
               <flexibleDose minDose="20.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="2627" size="52">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2627"/>
               <rateMeasurement rate="9" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2625"/>
               <rateMeasurement rate="1" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="2625"/>
               <rateMeasurement rate="4" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2627"/>
               <rateMeasurement rate="7" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2627"/>
               <rateMeasurement rate="4" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2625"/>
               <rateMeasurement rate="6" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2625"/>
               <rateMeasurement rate="3" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2627"/>
               <rateMeasurement rate="6" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2627"/>
               <rateMeasurement rate="3" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2627"/>
               <rateMeasurement rate="2" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2625"/>
               <rateMeasurement rate="4" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2625"/>
               <rateMeasurement rate="4" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2625"/>
               <rateMeasurement rate="1" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2627"/>
               <rateMeasurement rate="6" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vertigo"/>
               <arm id="2625"/>
               <rateMeasurement rate="4" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2625"/>
               <rateMeasurement rate="21" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2627"/>
               <rateMeasurement rate="5" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm id="2627"/>
               <rateMeasurement rate="4" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2625"/>
               <rateMeasurement rate="4" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2627"/>
               <rateMeasurement rate="3" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2625"/>
               <rateMeasurement rate="1" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2625"/>
               <rateMeasurement rate="5" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="2627"/>
               <rateMeasurement rate="2" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2627"/>
               <rateMeasurement rate="7" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2625"/>
               <rateMeasurement rate="8" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2627"/>
               <rateMeasurement rate="2" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vertigo"/>
               <arm id="2627"/>
               <rateMeasurement rate="4" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2627"/>
               <rateMeasurement rate="4" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2625"/>
               <rateMeasurement rate="3" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MADRS Responders"/>
               <arm id="2627"/>
               <rateMeasurement rate="9" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2625"/>
               <rateMeasurement rate="5" sampleSize="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2625"/>
               <rateMeasurement rate="20" sampleSize="54"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Sechter et al, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>45</value>
               <notes/>
            </centers>
            <objective>
               <value>A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients qualified for the trial if they fulfilled the DSM-III-R criteria for major depressive disorder and had a baseline 17-item HAM-D score of at least 20. Patients aged between 18–65 years of either sex were eligible, although women of child-bearing age were disqualified if they were pregnant, planned to become pregnant during the study period, or if they had not been using an effective contraceptive method for at least 3 months prior to the study. There was a wash-out period of duration of at least 1 week, increasing to 2 weeks if the patient had previously received monoamine oxidase inhibitors, and to a maximum of 5 weeks if the patient had previously been treated with fluoxetine.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded from the trial if they were receiving anticoagulants, serotonergic drugs, monoamine oxidase inhibitors or lithium, or if they were being treated for hypertension with reserpine or α-methyldopa. Other exclusion criteria included epilepsy, organic brain disease, malignancy, or severe disease or surgical intervention within the 4 weeks preceding the trial. Also excluded were patients with clinically significant dermatological, tumoral, haematological, endocrine, respiratory, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. All investigators were psychiatrists and were asked to carefully checked any other mental disorder (with the exception of depression) which was an exclusion criterion. Patients with a history of severe allergies or a known fluoxetine or lactose allergy were disqualified, as were patients who had been previously included in therapeutic trials with sertraline, or patients who had previously failed to respond to three or more antidepressant treatments. Finally patients with a history of alcoholic or drug dependence, psychosis, personality disorders, and patients with a significant suicide risk were excluded from the trial.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10572324</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anxiety">
               <adverseEvent name="Anxiety"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Gastralgia">
               <adverseEvent name="Gastralgia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2699" size="118">
               <flexibleDose minDose="50.0" maxDose="150.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Sertraline"/>
               <notes/>
            </arm>
            <arm id="2701" size="120">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2701"/>
               <rateMeasurement rate="76" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="2699"/>
               <rateMeasurement rate="2" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2699"/>
               <rateMeasurement rate="6" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm id="2701"/>
               <rateMeasurement rate="1" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2701"/>
               <rateMeasurement rate="2" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastralgia"/>
               <arm id="2699"/>
               <rateMeasurement rate="6" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2701"/>
               <rateMeasurement rate="5" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2701"/>
               <rateMeasurement rate="8" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2699"/>
               <rateMeasurement rate="1" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastralgia"/>
               <arm id="2701"/>
               <rateMeasurement rate="6" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2701"/>
               <rateMeasurement rate="2" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2701"/>
               <rateMeasurement rate="2" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2701"/>
               <rateMeasurement rate="2" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2701"/>
               <rateMeasurement rate="5" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2701"/>
               <rateMeasurement rate="40" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2699"/>
               <rateMeasurement rate="5" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2699"/>
               <rateMeasurement rate="27" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2699"/>
               <rateMeasurement rate="3" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2699"/>
               <rateMeasurement rate="6" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2701"/>
               <rateMeasurement rate="4" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2701"/>
               <rateMeasurement rate="2" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2699"/>
               <rateMeasurement rate="3" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anxiety"/>
               <arm id="2699"/>
               <rateMeasurement rate="4" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2701"/>
               <rateMeasurement rate="20" sampleSize="120"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2699"/>
               <rateMeasurement rate="86" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2699"/>
               <rateMeasurement rate="29" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2699"/>
               <rateMeasurement rate="4" sampleSize="118"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2699"/>
               <rateMeasurement rate="2" sampleSize="118"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Silverstone and Ravindran, 1999">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>We conducted a randomized, double-blind, placebo-controlled study of the efficacy and safety of once-daily venlafaxine extended release (XR) and fluoxetine in outpatients with major depression and concomitant anxiety.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Outpatients aged 18 years or older who met DSM-IV criteria for major depressive disorder were eligible if they had a minimum baseline score of 20 on the first 17 items of the 21-item HAM-D scale with no more than a 20% decrease in score between screening and baseline. They also had a minimum score of 8 on the Covi scale and symptoms of depression for at least 1 month before study entry.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Women who were pregnant, lactating, or of childbearing potential and had a positive beta-human chorionic gonadotropin (beta-hCG) pregnancy test result were not included. Also excluded were patients who had a history of clinically significant medical disease or clinically significant abnormalities on a screening physical examination, electrocardiogram (ECG), or laboratory tests. Thos who had acute suicidal tendencies, a history of seizure disorder, an organic mental disorder, bipolar disorder, or history of mania or any psychotic disorder not associated with depression were also excluded. Other reasons for exclusion were use of any investigational drug or electroconvulsive therapy within 30 days, fluoxetine within 28 days, or a monoamine oxidase inhibitor or paroxetine within 14 days of double-blind treatment. Patients could not have taken any other antidepressant, antipsychotic, anxiolytic, sedative-hypnotic drug, or psychotropic drug or substance within 7 days of the start of double-blind treatment; any nonpsychopharmacologic drug with psychotropic effects (e.g., beta-andrenergic blockers) within 7 days of baseline unless the dosage had been stable for a minimum of 1 month before double-blind treatment. Patients with a history of drug or alcohol dependence within 2 years or a history of drug abuse within 6 months of the start of double-blind treatment were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10074873</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nervousness">
               <adverseEvent name="Nervousness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2765" size="128">
               <flexibleDose minDose="75.0" maxDose="225.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="2767" size="121">
               <flexibleDose minDose="20.0" maxDose="60.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
            <arm id="2769" size="119">
               <fixedDose quantity="0.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Placebo"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2765"/>
               <rateMeasurement rate="84" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2765"/>
               <rateMeasurement rate="23" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2769"/>
               <rateMeasurement rate="20" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2765"/>
               <rateMeasurement rate="49" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2765"/>
               <rateMeasurement rate="13" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2765"/>
               <rateMeasurement rate="17" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2767"/>
               <rateMeasurement rate="8" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2765"/>
               <rateMeasurement rate="37" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2769"/>
               <rateMeasurement rate="12" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2767"/>
               <rateMeasurement rate="12" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2765"/>
               <rateMeasurement rate="13" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2769"/>
               <rateMeasurement rate="12" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm id="2769"/>
               <rateMeasurement rate="4" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2769"/>
               <rateMeasurement rate="3" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2769"/>
               <rateMeasurement rate="14" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2767"/>
               <rateMeasurement rate="22" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2769"/>
               <rateMeasurement rate="48" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2769"/>
               <rateMeasurement rate="7" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2765"/>
               <rateMeasurement rate="36" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2767"/>
               <rateMeasurement rate="14" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2767"/>
               <rateMeasurement rate="21" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2765"/>
               <rateMeasurement rate="30" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2765"/>
               <rateMeasurement rate="41" sampleSize="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2767"/>
               <rateMeasurement rate="30" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2767"/>
               <rateMeasurement rate="17" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2767"/>
               <rateMeasurement rate="77" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2769"/>
               <rateMeasurement rate="50" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nervousness"/>
               <arm id="2769"/>
               <rateMeasurement rate="8" sampleSize="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2767"/>
               <rateMeasurement rate="32" sampleSize="121"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2767"/>
               <rateMeasurement rate="22" sampleSize="121"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Tylee et al, 1997">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice.

Primary Care Psychiatry 1997; 3: 51-58</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>To evaluate the comparative efficacy and safety of venlafaxine and fluoxetine for the treatment of depression in general practice.</value>
               <notes/>
            </objective>
            <inclusion>
               <value> - &gt;= 18 years of age
 - Met DSM-IV criteria for major depression
 - Baseline MADRS &gt;= 19
 - Depressive symptoms for at least 14 days before entry</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value> - Use of study drugs within 1 month of entry
 - History of psychosis
 - Presense of organic mental disorder
 - Bipolar depression
 - Acutely suicidal
 - Use of psychoactive drugs/electroconvulsive therapy within 1 month of entry
 - Drug/alcohol dependence
 - History of clinically significant physical disorder
 - Clinically significant abnormalities on physical examination, electrocardiogram or laboratory tests
 - Pregnancy or lactation</value>
               <notes/>
            </exclusion>
            <references/>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Pharyngitis">
               <adverseEvent name="Pharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Infection">
               <adverseEvent name="Infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Sweating">
               <adverseEvent name="Sweating"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Flu Syndrome">
               <adverseEvent name="Flu Syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2837" size="171">
               <fixedDose quantity="75.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Venlafaxine"/>
               <notes/>
            </arm>
            <arm id="2839" size="170">
               <fixedDose quantity="20.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Fluoxetine"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2839"/>
               <rateMeasurement rate="5" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2837"/>
               <rateMeasurement rate="12" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2839"/>
               <rateMeasurement rate="9" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2839"/>
               <rateMeasurement rate="29" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2839"/>
               <rateMeasurement rate="58" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2839"/>
               <rateMeasurement rate="4" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2837"/>
               <rateMeasurement rate="13" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngitis"/>
               <arm id="2839"/>
               <rateMeasurement rate="8" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2839"/>
               <rateMeasurement rate="11" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngitis"/>
               <arm id="2837"/>
               <rateMeasurement rate="9" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="2837"/>
               <rateMeasurement rate="7" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2839"/>
               <rateMeasurement rate="11" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2837"/>
               <rateMeasurement rate="19" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2837"/>
               <rateMeasurement rate="19" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2837"/>
               <rateMeasurement rate="67" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2839"/>
               <rateMeasurement rate="31" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2839"/>
               <rateMeasurement rate="46" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2839"/>
               <rateMeasurement rate="8" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2837"/>
               <rateMeasurement rate="59" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2837"/>
               <rateMeasurement rate="7" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm id="2837"/>
               <rateMeasurement rate="22" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2839"/>
               <rateMeasurement rate="8" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm id="2839"/>
               <rateMeasurement rate="9" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2837"/>
               <rateMeasurement rate="47" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2839"/>
               <rateMeasurement rate="2" sampleSize="170"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Flu Syndrome"/>
               <arm id="2837"/>
               <rateMeasurement rate="10" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating"/>
               <arm id="2837"/>
               <rateMeasurement rate="10" sampleSize="171"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Infection"/>
               <arm id="2837"/>
               <rateMeasurement rate="9" sampleSize="171"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
      <study name="Weihs et al, 2000">
         <indication name="Severe depression">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <objective>
               <value>This study compared the efficacy and safety of bupropion sustained release (SR) with the selective serotonin reuptake inhibitor paroxetine in the treatment of major depression in elderly outpatients.</value>
               <notes/>
            </objective>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women 60 years of age and older with a minimum baseline score of 18 on the 21-item Hamilton Rating Scale for Depression (HAM-D) who presented with a recurrent episode of nonpsychotic major depressive disorder (DSM-IV) with a duration of at least 8 weeks, but not more than 24 months, and who were considered clinically appropriate for treatment with either bupropion SR or paroxetine were eligible for the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients who had a known predisposition to seizures were excluded from the study. Patients taking medications or treatments that lower the seizure threshold were also excluded. Patients were excluded if they were actively suicidal, had a history or current diagnosis of anorexia nervosa or bulimia nervosa, had an unstable medical disorder, or had a history of nonresponsiveness to pharmacotherapy for depression. Patients were also excluded if they had a history of alcohol or substance abuse within 1 year prior to the study or myocardial infarction, uncontrolled hypertension, or unstable heart disease within 6 months prior to the study. Patients could not have received any psychoactive drug within 1 week of the treatment phase of the study (2 weeks for MAOIs and 4 weeks for fluoxetine or investigational drugs) or have had previous treatment with bupropion or paroxetine.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>10817105</pubMedId>
            </references>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure id="endpoint-Dropouts">
               <endpoint name="Dropouts"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="endpoint-HAM-D Responders">
               <endpoint name="HAM-D Responders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Somnolence">
               <adverseEvent name="Somnolence"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dry Mouth">
               <adverseEvent name="Dry Mouth"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Agitation">
               <adverseEvent name="Agitation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm id="2902" size="52">
               <flexibleDose minDose="10.0" maxDose="40.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Paroxetine"/>
               <notes/>
            </arm>
            <arm id="2904" size="48">
               <flexibleDose minDose="100.0" maxDose="300.0" unit="MILLIGRAMS_A_DAY"/>
               <drug name="Bupropion"/>
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2904"/>
               <rateMeasurement rate="6" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2904"/>
               <rateMeasurement rate="1" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2904"/>
               <rateMeasurement rate="6" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2904"/>
               <rateMeasurement rate="17" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2902"/>
               <rateMeasurement rate="8" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2902"/>
               <rateMeasurement rate="11" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm id="2904"/>
               <rateMeasurement rate="3" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2904"/>
               <rateMeasurement rate="6" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm id="2902"/>
               <rateMeasurement rate="7" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2904"/>
               <rateMeasurement rate="3" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2902"/>
               <rateMeasurement rate="8" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="2902"/>
               <rateMeasurement rate="6" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm id="2902"/>
               <rateMeasurement rate="6" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2904"/>
               <rateMeasurement rate="34" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Agitation"/>
               <arm id="2904"/>
               <rateMeasurement rate="7" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm id="2904"/>
               <rateMeasurement rate="6" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HAM-D Responders"/>
               <arm id="2902"/>
               <rateMeasurement rate="40" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm id="2902"/>
               <rateMeasurement rate="10" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dry Mouth"/>
               <arm id="2902"/>
               <rateMeasurement rate="8" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm id="2902"/>
               <rateMeasurement rate="7" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Somnolence"/>
               <arm id="2902"/>
               <rateMeasurement rate="14" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2904"/>
               <rateMeasurement rate="2" sampleSize="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm id="2902"/>
               <rateMeasurement rate="8" sampleSize="52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Dropouts"/>
               <arm id="2904"/>
               <rateMeasurement rate="8" sampleSize="48"/>
            </measurement>
         </measurements>
         <notes/>
      </study>
   </studies>
	  <metaAnalyses>
      <pairwiseMetaAnalysis name="Fluox-Venla Diarrhea">
         <indication name="Severe depression"/>
         <adverseEvent name="Diarrhea"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="2839" study="Tylee et al, 1997"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="2837" study="Tylee et al, 1997"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <pairwiseMetaAnalysis name="Fluox-Venla Dizziness">
         <indication name="Severe depression"/>
         <adverseEvent name="Dizziness"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="2767" study="Silverstone and Ravindran, 1999"/>
               <arm id="175" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2765" study="Silverstone and Ravindran, 1999"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <pairwiseMetaAnalysis name="Fluox-Venla HAM-D">
         <indication name="Severe depression"/>
         <endpoint name="HAM-D Responders"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="964" study="De Nayer et al, 2002"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="2767" study="Silverstone and Ravindran, 1999"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="175" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="962" study="De Nayer et al, 2002"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2765" study="Silverstone and Ravindran, 1999"/>
               <arm id="1116" study="Dierick et al, 1996"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <pairwiseMetaAnalysis name="Fluox-Venla Headache">
         <indication name="Severe depression"/>
         <adverseEvent name="Headache"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="964" study="De Nayer et al, 2002"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="1118" study="Dierick et al, 1996"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="962" study="De Nayer et al, 2002"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="1116" study="Dierick et al, 1996"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <pairwiseMetaAnalysis name="Fluox-Venla Insomnia">
         <indication name="Severe depression"/>
         <adverseEvent name="Insomnia"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="2767" study="Silverstone and Ravindran, 1999"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="175" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="2765" study="Silverstone and Ravindran, 1999"/>
               <arm id="1116" study="Dierick et al, 1996"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <pairwiseMetaAnalysis name="Fluox-Venla Nausea">
         <indication name="Severe depression"/>
         <adverseEvent name="Nausea"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="964" study="De Nayer et al, 2002"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="175" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="962" study="De Nayer et al, 2002"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="1116" study="Dierick et al, 1996"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <networkMetaAnalysis name="Hansen Diarrhea">
         <indication name="Severe depression"/>
         <adverseEvent name="Diarrhea"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="1614" study="Gagiano 1993"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="642" study="Chouinard et al, 1999"/>
               <arm id="2303" study="Newhouse et al, 2000"/>
               <arm id="2701" study="Sechter et al, 1999"/>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="1350" study="Fava et al, 2002"/>
               <arm id="2627" study="Schone and Ludwig, 1993"/>
               <arm id="454" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Paroxetine"/>
            <arms>
               <arm id="1612" study="Gagiano 1993"/>
               <arm id="228" study="Ballus et al, 2000"/>
               <arm id="640" study="Chouinard et al, 1999"/>
               <arm id="83" study="Aberg-Wistedt et al, 2000"/>
               <arm id="2017" study="McPartlin et al, 1998"/>
               <arm id="1348" study="Fava et al, 2002"/>
               <arm id="2625" study="Schone and Ludwig, 1993"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="226" study="Ballus et al, 2000"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2080" study="Mehtonen et al, 2000"/>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="2015" study="McPartlin et al, 1998"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Sertraline"/>
            <arms>
               <arm id="2301" study="Newhouse et al, 2000"/>
               <arm id="2699" study="Sechter et al, 1999"/>
               <arm id="2082" study="Mehtonen et al, 2000"/>
               <arm id="85" study="Aberg-Wistedt et al, 2000"/>
               <arm id="1346" study="Fava et al, 2002"/>
               <arm id="452" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
      </networkMetaAnalysis>
      <networkMetaAnalysis name="Hansen Dizziness">
         <indication name="Severe depression"/>
         <adverseEvent name="Dizziness"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="2767" study="Silverstone and Ravindran, 1999"/>
               <arm id="1350" study="Fava et al, 2002"/>
               <arm id="2303" study="Newhouse et al, 2000"/>
               <arm id="2627" study="Schone and Ludwig, 1993"/>
               <arm id="175" study="Alves et al, 1999"/>
               <arm id="454" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2015" study="McPartlin et al, 1998"/>
               <arm id="2765" study="Silverstone and Ravindran, 1999"/>
               <arm id="2080" study="Mehtonen et al, 2000"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Sertraline"/>
            <arms>
               <arm id="85" study="Aberg-Wistedt et al, 2000"/>
               <arm id="1346" study="Fava et al, 2002"/>
               <arm id="2301" study="Newhouse et al, 2000"/>
               <arm id="2082" study="Mehtonen et al, 2000"/>
               <arm id="452" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Paroxetine"/>
            <arms>
               <arm id="83" study="Aberg-Wistedt et al, 2000"/>
               <arm id="2017" study="McPartlin et al, 1998"/>
               <arm id="1348" study="Fava et al, 2002"/>
               <arm id="2625" study="Schone and Ludwig, 1993"/>
            </arms>
         </alternative>
      </networkMetaAnalysis>
      <networkMetaAnalysis name="Hansen HAM-D">
         <indication name="Severe depression"/>
         <endpoint name="HAM-D Responders"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="550" study="Boyer et al, 1998"/>
               <arm id="1614" study="Gagiano 1993"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="642" study="Chouinard et al, 1999"/>
               <arm id="2767" study="Silverstone and Ravindran, 1999"/>
               <arm id="2701" study="Sechter et al, 1999"/>
               <arm id="2303" study="Newhouse et al, 2000"/>
               <arm id="990" study="De Wilde et al, 1993"/>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="964" study="De Nayer et al, 2002"/>
               <arm id="1350" study="Fava et al, 2002"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="2627" study="Schone and Ludwig, 1993"/>
               <arm id="175" study="Alves et al, 1999"/>
               <arm id="1306" study="Fava et al, 1998"/>
               <arm id="454" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Sertraline"/>
            <arms>
               <arm id="548" study="Boyer et al, 1998"/>
               <arm id="2699" study="Sechter et al, 1999"/>
               <arm id="2301" study="Newhouse et al, 2000"/>
               <arm id="2082" study="Mehtonen et al, 2000"/>
               <arm id="1346" study="Fava et al, 2002"/>
               <arm id="452" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Paroxetine"/>
            <arms>
               <arm id="1612" study="Gagiano 1993"/>
               <arm id="228" study="Ballus et al, 2000"/>
               <arm id="640" study="Chouinard et al, 1999"/>
               <arm id="988" study="De Wilde et al, 1993"/>
               <arm id="2017" study="McPartlin et al, 1998"/>
               <arm id="1348" study="Fava et al, 2002"/>
               <arm id="2625" study="Schone and Ludwig, 1993"/>
               <arm id="1304" study="Fava et al, 1998"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="226" study="Ballus et al, 2000"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2765" study="Silverstone and Ravindran, 1999"/>
               <arm id="2080" study="Mehtonen et al, 2000"/>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="962" study="De Nayer et al, 2002"/>
               <arm id="2015" study="McPartlin et al, 1998"/>
               <arm id="1116" study="Dierick et al, 1996"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
      </networkMetaAnalysis>
      <networkMetaAnalysis name="Hansen Headache">
         <indication name="Severe depression"/>
         <adverseEvent name="Headache"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="1614" study="Gagiano 1993"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="642" study="Chouinard et al, 1999"/>
               <arm id="2303" study="Newhouse et al, 2000"/>
               <arm id="2701" study="Sechter et al, 1999"/>
               <arm id="964" study="De Nayer et al, 2002"/>
               <arm id="1350" study="Fava et al, 2002"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="2627" study="Schone and Ludwig, 1993"/>
               <arm id="454" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Paroxetine"/>
            <arms>
               <arm id="1612" study="Gagiano 1993"/>
               <arm id="228" study="Ballus et al, 2000"/>
               <arm id="640" study="Chouinard et al, 1999"/>
               <arm id="83" study="Aberg-Wistedt et al, 2000"/>
               <arm id="2017" study="McPartlin et al, 1998"/>
               <arm id="1348" study="Fava et al, 2002"/>
               <arm id="2625" study="Schone and Ludwig, 1993"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="226" study="Ballus et al, 2000"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2080" study="Mehtonen et al, 2000"/>
               <arm id="962" study="De Nayer et al, 2002"/>
               <arm id="2015" study="McPartlin et al, 1998"/>
               <arm id="1116" study="Dierick et al, 1996"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Sertraline"/>
            <arms>
               <arm id="2301" study="Newhouse et al, 2000"/>
               <arm id="2699" study="Sechter et al, 1999"/>
               <arm id="2082" study="Mehtonen et al, 2000"/>
               <arm id="85" study="Aberg-Wistedt et al, 2000"/>
               <arm id="1346" study="Fava et al, 2002"/>
               <arm id="452" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
      </networkMetaAnalysis>
      <networkMetaAnalysis name="Hansen Insomnia">
         <indication name="Severe depression"/>
         <adverseEvent name="Insomnia"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="1614" study="Gagiano 1993"/>
               <arm id="642" study="Chouinard et al, 1999"/>
               <arm id="2767" study="Silverstone and Ravindran, 1999"/>
               <arm id="2303" study="Newhouse et al, 2000"/>
               <arm id="2701" study="Sechter et al, 1999"/>
               <arm id="1350" study="Fava et al, 2002"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="2627" study="Schone and Ludwig, 1993"/>
               <arm id="175" study="Alves et al, 1999"/>
               <arm id="1306" study="Fava et al, 1998"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Paroxetine"/>
            <arms>
               <arm id="1612" study="Gagiano 1993"/>
               <arm id="228" study="Ballus et al, 2000"/>
               <arm id="640" study="Chouinard et al, 1999"/>
               <arm id="2017" study="McPartlin et al, 1998"/>
               <arm id="1348" study="Fava et al, 2002"/>
               <arm id="2625" study="Schone and Ludwig, 1993"/>
               <arm id="1304" study="Fava et al, 1998"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="226" study="Ballus et al, 2000"/>
               <arm id="2765" study="Silverstone and Ravindran, 1999"/>
               <arm id="2080" study="Mehtonen et al, 2000"/>
               <arm id="2015" study="McPartlin et al, 1998"/>
               <arm id="1116" study="Dierick et al, 1996"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Sertraline"/>
            <arms>
               <arm id="2301" study="Newhouse et al, 2000"/>
               <arm id="2699" study="Sechter et al, 1999"/>
               <arm id="2082" study="Mehtonen et al, 2000"/>
               <arm id="1346" study="Fava et al, 2002"/>
            </arms>
         </alternative>
      </networkMetaAnalysis>
      <networkMetaAnalysis name="Hansen Nausea">
         <indication name="Severe depression"/>
         <adverseEvent name="Nausea"/>
         <alternative>
            <drug name="Fluoxetine"/>
            <arms>
               <arm id="1614" study="Gagiano 1993"/>
               <arm id="2839" study="Tylee et al, 1997"/>
               <arm id="642" study="Chouinard et al, 1999"/>
               <arm id="2303" study="Newhouse et al, 2000"/>
               <arm id="2701" study="Sechter et al, 1999"/>
               <arm id="990" study="De Wilde et al, 1993"/>
               <arm id="2461" study="Rudolph and Feiger, 1999"/>
               <arm id="964" study="De Nayer et al, 2002"/>
               <arm id="1350" study="Fava et al, 2002"/>
               <arm id="1118" study="Dierick et al, 1996"/>
               <arm id="2627" study="Schone and Ludwig, 1993"/>
               <arm id="175" study="Alves et al, 1999"/>
               <arm id="454" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Paroxetine"/>
            <arms>
               <arm id="1612" study="Gagiano 1993"/>
               <arm id="228" study="Ballus et al, 2000"/>
               <arm id="640" study="Chouinard et al, 1999"/>
               <arm id="988" study="De Wilde et al, 1993"/>
               <arm id="83" study="Aberg-Wistedt et al, 2000"/>
               <arm id="2017" study="McPartlin et al, 1998"/>
               <arm id="1348" study="Fava et al, 2002"/>
               <arm id="2625" study="Schone and Ludwig, 1993"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Venlafaxine"/>
            <arms>
               <arm id="226" study="Ballus et al, 2000"/>
               <arm id="2837" study="Tylee et al, 1997"/>
               <arm id="2080" study="Mehtonen et al, 2000"/>
               <arm id="2459" study="Rudolph and Feiger, 1999"/>
               <arm id="962" study="De Nayer et al, 2002"/>
               <arm id="2015" study="McPartlin et al, 1998"/>
               <arm id="1116" study="Dierick et al, 1996"/>
               <arm id="173" study="Alves et al, 1999"/>
            </arms>
         </alternative>
         <alternative>
            <drug name="Sertraline"/>
            <arms>
               <arm id="2301" study="Newhouse et al, 2000"/>
               <arm id="2699" study="Sechter et al, 1999"/>
               <arm id="2082" study="Mehtonen et al, 2000"/>
               <arm id="85" study="Aberg-Wistedt et al, 2000"/>
               <arm id="1346" study="Fava et al, 2002"/>
               <arm id="452" study="Bennie et al, 1995"/>
            </arms>
         </alternative>
      </networkMetaAnalysis>
   </metaAnalyses>
	  <benefitRiskAnalyses>
      <studyBenefitRiskAnalysis name="Benkert HAM-D/weight gain" analysisType="LyndOBrien">
         <indication name="Severe depression"/>
         <study name="Benkert et al, 2000"/>
         <arms>
            <arm id="368" study="Benkert et al, 2000"/>
            <arm id="366" study="Benkert et al, 2000"/>
         </arms>
         <outcomeMeasures>
            <endpoint name="HAM-D Responders"/>
            <adverseEvent name="Weight Gain"/>
         </outcomeMeasures>
      </studyBenefitRiskAnalysis>
      <studyBenefitRiskAnalysis name="Fava et al, 2002 BR" analysisType="SMAA">
         <indication name="Severe depression"/>
         <study name="Fava et al, 2002"/>
         <arms>
            <arm id="1346" study="Fava et al, 2002"/>
            <arm id="1350" study="Fava et al, 2002"/>
            <arm id="1348" study="Fava et al, 2002"/>
         </arms>
         <outcomeMeasures>
            <adverseEvent name="Nausea"/>
            <adverseEvent name="Diarrhea"/>
            <endpoint name="HAM-D Responders"/>
            <adverseEvent name="Headache"/>
            <adverseEvent name="Insomnia"/>
            <adverseEvent name="Dizziness"/>
         </outcomeMeasures>
      </studyBenefitRiskAnalysis>
      <metaBenefitRiskAnalysis name="Fluox-Venla BR" analysisType="SMAA">
         <indication name="Severe depression"/>
         <baseline name="Fluoxetine"/>
         <drugs>
            <drug name="Fluoxetine"/>
            <drug name="Venlafaxine"/>
         </drugs>
         <metaAnalyses>
            <metaAnalysis name="Fluox-Venla Diarrhea"/>
            <metaAnalysis name="Fluox-Venla Dizziness"/>
            <metaAnalysis name="Fluox-Venla HAM-D"/>
            <metaAnalysis name="Fluox-Venla Headache"/>
            <metaAnalysis name="Fluox-Venla Insomnia"/>
            <metaAnalysis name="Fluox-Venla Nausea"/>
         </metaAnalyses>
      </metaBenefitRiskAnalysis>
      <metaBenefitRiskAnalysis name="Hansen BR" analysisType="SMAA">
         <indication name="Severe depression"/>
         <baseline name="Fluoxetine"/>
         <drugs>
            <drug name="Fluoxetine"/>
            <drug name="Paroxetine"/>
            <drug name="Sertraline"/>
            <drug name="Venlafaxine"/>
         </drugs>
         <metaAnalyses>
            <metaAnalysis name="Hansen Diarrhea"/>
            <metaAnalysis name="Hansen Dizziness"/>
            <metaAnalysis name="Hansen HAM-D"/>
            <metaAnalysis name="Hansen Headache"/>
            <metaAnalysis name="Hansen Insomnia"/>
            <metaAnalysis name="Hansen Nausea"/>
         </metaAnalyses>
      </metaBenefitRiskAnalysis>
   </benefitRiskAnalyses>
</addis-data>